BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, Yamamoto S, Tatsuno K, Katoh H, Watanabe Y, Ichimura T, Ushiku T, Funahashi S, Tateishi K, Wada I, Shimizu N, Nomura S, Koike K, Seto Y, Fukayama M, Aburatani H, Ishikawa S. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014;46:583-587. [PMID: 24816255 DOI: 10.1038/ng.2984] [Cited by in Crossref: 305] [Cited by in F6Publishing: 295] [Article Influence: 38.1] [Reference Citation Analysis]
Number Citing Articles
1 Svensmark JH, Brakebusch C. Rho GTPases in cancer: friend or foe? Oncogene 2019;38:7447-56. [PMID: 31427738 DOI: 10.1038/s41388-019-0963-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 12.7] [Reference Citation Analysis]
2 Katoh H, Ishikawa S. Lifestyles, genetics, and future perspectives on gastric cancer in east Asian populations. J Hum Genet 2021;66:887-99. [PMID: 34267306 DOI: 10.1038/s10038-021-00960-8] [Reference Citation Analysis]
3 Hashimoto T, Ogawa R, Tang T, Yoshida H, Taniguchi H, Katai H, Oda I, Sekine S. RHOA mutations and CLDN18-ARHGAP fusions in intestinal-type adenocarcinoma with anastomosing glands of the stomach. Mod Pathol 2019;32:568-75. [DOI: 10.1038/s41379-018-0181-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Tanaka Y, Chiwaki F, Kojima S, Kawazu M, Komatsu M, Ueno T, Inoue S, Sekine S, Matsusaki K, Matsushita H, Boku N, Kanai Y, Yatabe Y, Sasaki H, Mano H. Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities. Nat Cancer 2021;2:962-77. [PMID: 35121863 DOI: 10.1038/s43018-021-00240-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
5 Nagaraja AK, Kikuchi O, Bass AJ. Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma. Cancer Discov 2019;9:1656-72. [PMID: 31727671 DOI: 10.1158/2159-8290.CD-19-0487] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
6 Lopez G, Venetis K, Sajjadi E, Fusco N. Mismatch Repair System Genomic Scars in Gastroesophageal Cancers: Biology and Clinical Testing. GastrointestDisord 2020;2:341-52. [DOI: 10.3390/gidisord2040031] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Shu Y, Zhang W, Hou Q, Zhao L, Zhang S, Zhou J, Song X, Zhang Y, Jiang D, Chen X, Wang P, Xia X, Liao F, Yin D, Chen X, Zhou X, Zhang D, Yin S, Yang K, Liu J, Fu L, Zhang L, Wang Y, Zhang J, An Y, Cheng H, Zheng B, Sun H, Zhao Y, Wang Y, Xie D, Ouyang L, Wang P, Zhang W, Qiu M, Fu X, Dai L, He G, Yang H, Cheng W, Yang L, Liu B, Li W, Dong B, Zhou Z, Wei Y, Peng Y, Xu H, Hu J. Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer. Nat Commun. 2018;9:2447. [PMID: 29961079 DOI: 10.1038/s41467-018-04907-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
8 Vettore AL, Ramnarayanan K, Poore G, Lim K, Ong CK, Huang KK, Leong HS, Chong FT, Lim TK, Lim WK, Cutcutache I, Mcpherson JR, Suzuki Y, Zhang S, Skanthakumar T, Wang W, Tan DS, Cho BC, Teh BT, Rozen S, Tan P, Iyer NG. Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance. Genome Med 2015;7:98. [PMID: 26395002 DOI: 10.1186/s13073-015-0219-2] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 8.4] [Reference Citation Analysis]
9 Kumar RD, Swamidass SJ, Bose R. Unsupervised detection of cancer driver mutations with parsimony-guided learning. Nat Genet 2016;48:1288-94. [PMID: 27618449 DOI: 10.1038/ng.3658] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
10 Röcken C, Behrens HM, Böger C, Krüger S. Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort. J Clin Pathol 2016;69:70-5. [PMID: 26251521 DOI: 10.1136/jclinpath-2015-202980] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
11 Abate F, Ambrosio MR, Mundo L, Laginestra MA, Fuligni F, Rossi M, Zairis S, Gazaneo S, De Falco G, Lazzi S, Bellan C, Rocca BJ, Amato T, Marasco E, Etebari M, Ogwang M, Calbi V, Ndede I, Patel K, Chumba D, Piccaluga PP, Pileri S, Leoncini L, Rabadan R. Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma. PLoS Pathog 2015;11:e1005158. [PMID: 26468873 DOI: 10.1371/journal.ppat.1005158] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 9.9] [Reference Citation Analysis]
12 Ueyama T. Rho-Family Small GTPases: From Highly Polarized Sensory Neurons to Cancer Cells. Cells 2019;8:E92. [PMID: 30696065 DOI: 10.3390/cells8020092] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
13 Nguyen PN, Tran NTB, Nguyen TPX, Ngo TNM, Lai DV, Deel CD, Hassell LA, Vuong HG. Clinicopathological Implications of RHOA Mutations in Angioimmunoblastic T-Cell Lymphoma: A Meta-analysis: RHOA mutations in AITL. Clin Lymphoma Myeloma Leuk 2021;21:431-8. [PMID: 33849798 DOI: 10.1016/j.clml.2021.03.002] [Reference Citation Analysis]
14 Riquelme I, Saavedra K, Espinoza JA, Weber H, García P, Nervi B, Garrido M, Corvalán AH, Roa JC, Bizama C. Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget 2015;6:24750-79. [PMID: 26267324 DOI: 10.18632/oncotarget.4990] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 13.0] [Reference Citation Analysis]
15 Carrasco-Garcia E, García-Puga M, Arevalo S, Matheu A. Towards precision medicine: linking genetic and cellular heterogeneity in gastric cancer. Ther Adv Med Oncol 2018;10:1758835918794628. [PMID: 30181784 DOI: 10.1177/1758835918794628] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
16 Nomura M, Saito K, Aihara K, Nagae G, Yamamoto S, Tatsuno K, Ueda H, Fukuda S, Umeda T, Tanaka S, Takayanagi S, Otani R, Nejo T, Hana T, Takahashi S, Kitagawa Y, Omata M, Higuchi F, Nakamura T, Muragaki Y, Narita Y, Nagane M, Nishikawa R, Ueki K, Saito N, Aburatani H, Mukasa A. DNA demethylation is associated with malignant progression of lower-grade gliomas. Sci Rep 2019;9:1903. [PMID: 30760837 DOI: 10.1038/s41598-019-38510-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
17 Kalpana G, Figy C, Yeung M, Yeung KC. Reduced RhoA expression enhances breast cancer metastasis with a concomitant increase in CCR5 and CXCR4 chemokines signaling. Sci Rep 2019;9:16351. [PMID: 31705019 DOI: 10.1038/s41598-019-52746-w] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
18 Kato M, Nishihara H, Hayashi H, Kimura T, Ishida Y, Wang L, Tsuda M, Tanino MA, Tanaka S. Clinicopathological evaluation of Sox10 expression in diffuse-type gastric adenocarcinoma. Med Oncol 2017;34. [DOI: 10.1007/s12032-016-0865-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chen J, Herlong FH, Stroehlein JR, Mishra L. Mutations of Chromatin Structure Regulating Genes in Human Malignancies. Curr Protein Pept Sci 2016;17:411-37. [PMID: 26796307 DOI: 10.2174/1389203717666160122120008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
20 Goldenring JR. The AGA/Funderburg Award in Gastric Cancer: Twenty-five Years of Advances in Gastric Cancer Research. Gastroenterology 2017;152:1262-6. [PMID: 28327368 DOI: 10.1053/j.gastro.2017.03.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Clark AD, Oldenbroek M, Boyer TG. Mediator kinase module and human tumorigenesis. Crit Rev Biochem Mol Biol 2015;50:393-426. [PMID: 26182352 DOI: 10.3109/10409238.2015.1064854] [Cited by in F6Publishing: 46] [Reference Citation Analysis]
22 Chang KK, Cho SJ, Yoon C, Lee JH, Park DJ, Yoon SS. Increased RhoA Activity Predicts Worse Overall Survival in Patients Undergoing Surgical Resection for Lauren Diffuse-Type Gastric Adenocarcinoma. Ann Surg Oncol 2016;23:4238-46. [PMID: 27364501 DOI: 10.1245/s10434-016-5357-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Yuen ST, Leung SY. Genomics Study of Gastric Cancer and Its Molecular Subtypes. Adv Exp Med Biol 2016;908:419-39. [PMID: 27573784 DOI: 10.1007/978-3-319-41388-4_21] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
24 Mondragón L, Mhaidly R, De Donatis GM, Tosolini M, Dao P, Martin AR, Pons C, Chiche J, Jacquin M, Imbert V, Proïcs E, Boyer L, Doye A, Luciano F, Neels JG, Coutant F, Fabien N, Sormani L, Rubio-Patiño C, Bossowski JP, Muller F, Marchetti S, Villa E, Peyron JF, Gaulard P, Lemonnier F, Asnafi V, Genestier L, Benhida R, Fournié JJ, Passeron T, Ricci JE, Verhoeyen E. GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF-κB-Dependent Mechanism. Cancer Cell 2019;36:268-287.e10. [PMID: 31447347 DOI: 10.1016/j.ccell.2019.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
25 van der Post RS, Gullo I, Oliveira C, Tang LH, Grabsch HI, O'Donovan M, Fitzgerald RC, van Krieken H, Carneiro F. Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future. Adv Exp Med Biol 2016;908:371-91. [PMID: 27573781 DOI: 10.1007/978-3-319-41388-4_18] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
26 Bleaney CW, Barrow M, Hayes S, Ang Y. The relevance and implications of signet-ring cell adenocarcinoma of the oesophagus. J Clin Pathol 2018;71:201-6. [PMID: 29212656 DOI: 10.1136/jclinpath-2017-204863] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
27 Korourian A, Roudi R, Shariftabrizi A, Madjd Z. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Exp Biol Med (Maywood). 2017;242:1842-1847. [PMID: 28836853 DOI: 10.1177/1535370217728460] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
28 Olson MF. Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors. Small GTPases 2018;9:203-15. [PMID: 27548350 DOI: 10.1080/21541248.2016.1218407] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 8.5] [Reference Citation Analysis]
29 Li X, Pasche B, Zhang W, Chen K. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer. JAMA Oncol. 2018;4:1691-1698. [PMID: 30098163 DOI: 10.1001/jamaoncol.2018.2805] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 15.7] [Reference Citation Analysis]
30 Lawson CD, Der CJ. Filling GAPs in our knowledge: ARHGAP11A and RACGAP1 act as oncogenes in basal-like breast cancers. Small GTPases 2018;9:290-6. [PMID: 27657701 DOI: 10.1080/21541248.2016.1220350] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
31 Kim MS, Yoo NJ, Lee SH. Preferential occurrence of RHOA mutation in gastric and colorectal cancers. Pathology 2015;47:598-9. [PMID: 26352114 DOI: 10.1097/PAT.0000000000000305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
32 Chen K, Yang D, Li X, Sun B, Song F, Cao W, Brat DJ, Gao Z, Li H, Liang H. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci USA. 2015;112:1107-1112. [PMID: 25583476 DOI: 10.1073/pnas.1422640112] [Cited by in Crossref: 97] [Cited by in F6Publishing: 95] [Article Influence: 13.9] [Reference Citation Analysis]
33 Yasumoto M, Sakamoto E, Ogasawara S, Isobe T, Kizaki J, Sumi A, Kusano H, Akiba J, Torimura T, Akagi Y, Itadani H, Kobayashi T, Hasako S, Kumazaki M, Mizuarai S, Oie S, Yano H. Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer. Cancer Med 2017;6:235-44. [PMID: 27891760 DOI: 10.1002/cam4.959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
34 Lim B, Kim C, Kim JH, Kwon WS, Lee WS, Kim JM, Park JY, Kim HS, Park KH, Kim TS. Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. Oncotarget. 2016;7:8055-8066. [PMID: 26811494 DOI: 10.18632/oncotarget.6977] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
35 Cho SJ, Yoon C, Lee JH, Chang KK, Lin JX, Kim YH, Kook MC, Aksoy BA, Park DJ, Ashktorab H, Smoot DT, Schultz N, Yoon SS. KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition. Clin Cancer Res 2018;24:6556-69. [PMID: 30108106 DOI: 10.1158/1078-0432.CCR-17-1679] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
36 Cai H, Hou X, Ding Y, Fu Z, Wang L, Du Y. Prediction of gastric cancer prognosis in the next-generation sequencing era. Tradit Med Mod Med 2019;02:105-18. [DOI: 10.1142/s2575900019300029] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Zhou J, Hayakawa Y, Wang Timothy C, Bass Adam J. RhoA Mutations Identified in Diffuse Gastric Cancer. Cancer Cell. 2014;26:9-11. [PMID: 25026207 DOI: 10.1016/j.ccr.2014.06.022] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
38 Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, Wang Y, Scott A, Ma L, Huo L, Vicente D, Blum Murphy M, Shanbhag N, Tatlonghari G, Thomas I, Rogers J, Kobayashi M, Vykoukal J, Estrella JS, Roy-Chowdhuri S, Han G, Zhang S, Mao X, Song X, Zhang J, Gu J, Johnson RL, Calin GA, Peng G, Lee JS, Hanash SM, Futreal A, Wang Z, Wang L, Ajani JA. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut 2020;69:18-31. [PMID: 31171626 DOI: 10.1136/gutjnl-2018-318070] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
39 Sremac M, Paic F, Grubelic Ravic K, Serman L, Pavicic Dujmovic A, Brcic I, Krznaric Z, Nikuseva Martic T. Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma. Oncol Lett 2021;22:822. [PMID: 34691249 DOI: 10.3892/ol.2021.13083] [Reference Citation Analysis]
40 Huang KH, Lan YT, Chen MH, Chao Y, Lo SS, Li AF, Wu CW, Chiou SH, Yang MH, Shyr YM, Fang WL. The Correlation Between RhoA Expression and Clinicopathological Characteristics in Gastric Cancer Patients After Curative Surgery. World J Surg 2015;39:2289-99. [PMID: 26013205 DOI: 10.1007/s00268-015-3095-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
41 Porazinski S, Parkin A, Pajic M. Rho-ROCK Signaling in Normal Physiology and as a Key Player in Shaping the Tumor Microenvironment. Adv Exp Med Biol 2020;1223:99-127. [PMID: 32030687 DOI: 10.1007/978-3-030-35582-1_6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
42 Kiuru M, Busam KJ. The NF1 gene in tumor syndromes and melanoma. Lab Invest 2017;97:146-57. [PMID: 28067895 DOI: 10.1038/labinvest.2016.142] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 14.2] [Reference Citation Analysis]
43 Dong X, Song S, Li Y, Fan Y, Wang L, Wang R, Huo L, Scott A, Xu Y, Pizzi MP, Ma L, Wang Y, Jin J, Zhao W, Yao X, Johnson RL, Wang L, Wang Z, Peng G, Ajani JA. Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency. Gut 2021:gutjnl-2020-322660. [PMID: 33785559 DOI: 10.1136/gutjnl-2020-322660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Crosas-Molist E, Samain R, Kohlhammer L, Orgaz J, George S, Maiques O, Barcelo J, Sanz-Moreno V. RhoGTPase Signalling in Cancer Progression and Dissemination. Physiol Rev 2021. [PMID: 34541899 DOI: 10.1152/physrev.00045.2020] [Reference Citation Analysis]
45 Perrot-Applanat M, Vacher S, Pimpie C, Chemlali W, Derieux S, Pocard M, Bieche I. Differential gene expression in growth factors, epithelial mesenchymal transition and chemotaxis in the diffuse type compared with the intestinal type of gastric cancer. Oncol Lett 2019;18:674-86. [PMID: 31289541 DOI: 10.3892/ol.2019.10392] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
46 Katona BW, Rustgi AK. Gastric Cancer Genomics: Advances and Future Directions. Cell Mol Gastroenterol Hepatol. 2017;3:211-217. [PMID: 28275688 DOI: 10.1016/j.jcmgh.2017.01.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
47 Suárez-Arriaga MC, Ribas-Aparicio RM, Ruiz-Tachiquín ME. MicroRNAs in hereditary diffuse gastric cancer. Biomed Rep 2016;5:151-4. [PMID: 27446532 DOI: 10.3892/br.2016.706] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
48 Sanjeevaiah A, Cheedella N, Hester C, Porembka MR. Gastric Cancer: Recent Molecular Classification Advances, Racial Disparity, and Management Implications. J Oncol Pract 2018;14:217-24. [PMID: 29641950 DOI: 10.1200/JOP.17.00025] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 6.3] [Reference Citation Analysis]
49 Katoh H, Ishikawa S. Genomic pathobiology of gastric carcinoma: Genomic Profile of Gastric Carcinoma. Pathol Int 2017;67:63-71. [DOI: 10.1111/pin.12493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
50 Takahashi Y, Yamamichi N, Inada KI, Shiogama K, Sakurai K, Takeuchi C, Mizutani Y, Tsutsumi Y, Koike K. Nectin1 expression is frequently decreased in gastric cancers. Pathol Int 2018;68:557-62. [PMID: 30221498 DOI: 10.1111/pin.12721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
51 Pattison S, Mitchell C, Lade S, Leong T, Busuttil RA, Boussioutas A. Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer. PLoS One 2017;12:e0183891. [PMID: 28922362 DOI: 10.1371/journal.pone.0183891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
52 Yoon JH, Choi WS, Kim O, Choi BJ, Nam SW, Lee JY, Park WS. Gastrokine 1 inhibits gastric cancer cell migration and invasion by downregulating RhoA expression. Gastric Cancer 2017;20:274-85. [DOI: 10.1007/s10120-016-0617-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
53 Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev 2014;94:1287-312. [PMID: 25287865 DOI: 10.1152/physrev.00005.2014] [Cited by in Crossref: 795] [Cited by in F6Publishing: 759] [Article Influence: 99.4] [Reference Citation Analysis]
54 Hayakawa Y, Sethi N, Sepulveda AR, Bass AJ, Wang TC. Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? Nat Rev Cancer. 2016;16:305-318. [PMID: 27112208 DOI: 10.1038/nrc.2016.24] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 13.6] [Reference Citation Analysis]
55 Yang Y, Li L, He H, Shi M, He L, Liang S, Qi J, Chen W. Numb inhibits migration and promotes proliferation of colon cancer cells via RhoA/ROCK signaling pathway repression. Exp Cell Res 2022;411:113004. [PMID: 34990618 DOI: 10.1016/j.yexcr.2021.113004] [Reference Citation Analysis]
56 Sasaki N, Iwaya T, Chiba T, Fujita M, Ju Z, Endo F, Yaegashi M, Hachiya T, Sugimoto R, Sugai T, Siwak DR, Liotta LA, Lu Y, Mills GB, Nakagawa H, Nishizuka SS. Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA. PLoS One 2020;15:e0239966. [PMID: 33027286 DOI: 10.1371/journal.pone.0239966] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Sasaki M, Chiwaki F, Kuroda T, Komatsu M, Matsusaki K, Kohno T, Sasaki H, Ogiwara H. Efficacy of glutathione inhibitors for the treatment of ARID1A-deficient diffuse-type gastric cancers. Biochem Biophys Res Commun 2020;522:342-7. [PMID: 31761322 DOI: 10.1016/j.bbrc.2019.11.078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
58 Pinheiro H, Oliveira C, Seruca R, Carneiro F. Hereditary diffuse gastric cancer - pathophysiology and clinical management. Best Pract Res Clin Gastroenterol. 2014;28:1055-1068. [PMID: 25439071 DOI: 10.1016/j.bpg.2014.09.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
59 Ge S, Xia X, Ding C, Zhen B, Zhou Q, Feng J, Yuan J, Chen R, Li Y, Ge Z, Ji J, Zhang L, Wang J, Li Z, Lai Y, Hu Y, Li Y, Li Y, Gao J, Chen L, Xu J, Zhang C, Jung SY, Choi JM, Jain A, Liu M, Song L, Liu W, Guo G, Gong T, Huang Y, Qiu Y, Huang W, Shi T, Zhu W, Wang Y, He F, Shen L, Qin J. A proteomic landscape of diffuse-type gastric cancer. Nat Commun 2018;9:1012. [PMID: 29520031 DOI: 10.1038/s41467-018-03121-2] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 17.3] [Reference Citation Analysis]
60 Kohsaka S, Tatsuno K, Ueno T, Nagano M, Shinozaki-Ushiku A, Ushiku T, Takai D, Ikegami M, Kobayashi H, Kage H, Ando M, Hata K, Ueda H, Yamamoto S, Kojima S, Oseto K, Akaike K, Suehara Y, Hayashi T, Saito T, Takahashi F, Takahashi K, Takamochi K, Suzuki K, Nagayama S, Oda Y, Mimori K, Ishihara S, Yatomi Y, Nagase T, Nakajima J, Tanaka S, Fukayama M, Oda K, Nangaku M, Miyazono K, Miyagawa K, Aburatani H, Mano H. Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens. Cancer Sci 2019;110:1464-79. [PMID: 30737998 DOI: 10.1111/cas.13968] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
61 Shimizu A, Zankov DP, Kurokawa-Seo M, Ogita H. Vascular Endothelial Growth Factor-A Exerts Diverse Cellular Effects via Small G Proteins, Rho and Rap. Int J Mol Sci 2018;19:E1203. [PMID: 29659486 DOI: 10.3390/ijms19041203] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
62 Sakata-yanagimoto M. Multistep tumorigenesis in peripheral T cell lymphoma. Int J Hematol 2015;102:523-7. [DOI: 10.1007/s12185-015-1738-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
63 Miyoshi H, Sakata-Yanagimoto M, Shimono J, Yoshida N, Hattori K, Arakawa F, Yanagida E, Takeuchi M, Yamada K, Suzuki T, Moritsubo M, Furuta T, Chiba S, Ohshima K. RHOA mutation in follicular T-cell lymphoma: Clinicopathological analysis of 16 cases. Pathol Int 2020;70:653-60. [PMID: 32648273 DOI: 10.1111/pin.12981] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
64 Olayioye MA, Noll B, Hausser A. Spatiotemporal Control of Intracellular Membrane Trafficking by Rho GTPases. Cells 2019;8:E1478. [PMID: 31766364 DOI: 10.3390/cells8121478] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
65 Buttura JR, Provisor Santos MN, Valieris R, Drummond RD, Defelicibus A, Lima JP, Calsavara VF, Freitas HC, Cordeiro de Lima VC, Fernanda Bartelli T, Wiedner M, Rosales R, Gollob KJ, Loizou J, Dias-Neto E, Nunes DN, da Silva IT. Mutational Signatures Driven by Epigenetic Determinants Enable the Stratification of Patients with Gastric Cancer for Therapeutic Intervention. Cancers (Basel) 2021;13:490. [PMID: 33513945 DOI: 10.3390/cancers13030490] [Reference Citation Analysis]
66 GE4GAC group. Genomics and epidemiology for gastric adenocarcinomas. Appl Cancer Res 2017;37. [DOI: 10.1186/s41241-017-0011-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
67 Fujisawa M, Sakata-Yanagimoto M, Nishizawa S, Komori D, Gershon P, Kiryu M, Tanzima S, Fukumoto K, Enami T, Muratani M, Yoshida K, Ogawa S, Matsue K, Nakamura N, Takeuchi K, Izutsu K, Fujimoto K, Teshima T, Miyoshi H, Gaulard P, Ohshima K, Chiba S. Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. Leukemia 2018;32:694-702. [PMID: 28832024 DOI: 10.1038/leu.2017.273] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 10.4] [Reference Citation Analysis]
68 Cui J, Yin Y, Ma Q, Wang G, Olman V, Zhang Y, Chou WC, Hong CS, Zhang C, Cao S, Mao X, Li Y, Qin S, Zhao S, Jiang J, Hastings P, Li F, Xu Y. Comprehensive characterization of the genomic alterations in human gastric cancer. Int J Cancer. 2015;137:86-95. [PMID: 25422082 DOI: 10.1002/ijc.29352] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
69 Min L, Zhao Y, Zhu S, Qiu X, Cheng R, Xing J, Shao L, Guo S, Zhang S. Integrated Analysis Identifies Molecular Signatures and Specific Prognostic Factors for Different Gastric Cancer Subtypes. Transl Oncol 2017;10:99-107. [PMID: 28013168 DOI: 10.1016/j.tranon.2016.11.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
70 Yamamoto R, Osawa T, Sasaki Y, Yamamoto S, Anai M, Izumi K, Matsumura Y, Sakai J, Aburatani H, Mizokami A, Kodama T, Tanaka T. Overexpression of p54nrb/NONO induces differential EPHA6 splicing and contributes to castration-resistant prostate cancer growth. Oncotarget 2018;9:10510-24. [PMID: 29535823 DOI: 10.18632/oncotarget.24063] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
71 Marroncini G, Fibbi B, Errico A, Grappone C, Maggi M, Peri A. Effects of low extracellular sodium on proliferation and invasive activity of cancer cells in vitro. Endocrine 2020;67:473-84. [PMID: 31784880 DOI: 10.1007/s12020-019-02135-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
72 Yigit G, Saida K, DeMarzo D, Miyake N, Fujita A, Yang Tan T, White SM, Wadley A, Toliat MR, Motameny S, Franitza M, Stutterd CA, Chong PF, Kira R, Sengoku T, Ogata K, Guillen Sacoto MJ, Fresen C, Beck BB, Nürnberg P, Dieterich C, Wollnik B, Matsumoto N, Altmüller J. The recurrent postzygotic pathogenic variant p.Glu47Lys in RHOA causes a novel recognizable neuroectodermal phenotype. Hum Mutat 2020;41:591-9. [PMID: 31821646 DOI: 10.1002/humu.23964] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
73 Marroncini G, Anceschi C, Naldi L, Fibbi B, Baldanzi F, Martinelli S, Polvani S, Maggi M, Peri A. Low sodium and tolvaptan have opposite effects in human small cell lung cancer cells. Mol Cell Endocrinol 2021;:111419. [PMID: 34389446 DOI: 10.1016/j.mce.2021.111419] [Reference Citation Analysis]
74 Zhang R, Guo T, Ji L, Yin Y, Feng S, Lu W, Zhang F, Zhu M, Liu S, Jiang J, Zeng F. Development and Application of Patient-Derived Cancer Organoidsin Clinical Management of Gastrointestinal Cancer: A State-of-the-Art Review. Front Oncol 2021;11:716339. [PMID: 34778032 DOI: 10.3389/fonc.2021.716339] [Reference Citation Analysis]
75 Bustelo XR. RHO GTPases in cancer: known facts, open questions, and therapeutic challenges. Biochem Soc Trans 2018;46:741-60. [PMID: 29871878 DOI: 10.1042/BST20170531] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
76 Graziani V, Rodriguez-Hernandez I, Maiques O, Sanz-Moreno V. The amoeboid state as part of the epithelial-to-mesenchymal transition programme. Trends Cell Biol 2021:S0962-8924(21)00206-3. [PMID: 34836782 DOI: 10.1016/j.tcb.2021.10.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Tahara T, Tahara S, Horiguchi N, Okubo M, Terada T, Yamada H, Yoshida D, Omori T, Osaki H, Maeda K, Kamano T, Funasaka K, Nagasaka M, Nakagawa Y, Shibata T, Ohmiya N. Molecular subtyping of gastric cancer combining genetic and epigenetic anomalies provides distinct clinicopathological features and prognostic impacts. Hum Mutat 2019;40:347-54. [PMID: 30575210 DOI: 10.1002/humu.23700] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
78 Lee JY, Schizas M, Geyer FC, Selenica P, Piscuoglio S, Sakr RA, Ng CKY, Carniello JVS, Towers R, Giri DD, de Andrade VP, Papanastasiou AD, Viale A, Harris RS, Solit DB, Weigelt B, Reis-Filho JS, King TA. Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. Clin Cancer Res 2019;25:674-86. [PMID: 30185420 DOI: 10.1158/1078-0432.CCR-18-1103] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
79 Guo J, Yu W, Su H, Pang X. Genomic landscape of gastric cancer: molecular classification and potential targets. Sci China Life Sci. 2017;60:126-137. [PMID: 27460193 DOI: 10.1007/s11427-016-0034-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
80 Mészáros B, Zeke A, Reményi A, Simon I, Dosztányi Z. Systematic analysis of somatic mutations driving cancer: uncovering functional protein regions in disease development. Biol Direct 2016;11:23. [PMID: 27150584 DOI: 10.1186/s13062-016-0125-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
81 Katoh H, Komura D, Konishi H, Suzuki R, Yamamoto A, Kakiuchi M, Sato R, Ushiku T, Yamamoto S, Tatsuno K, Oshima T, Nomura S, Seto Y, Fukayama M, Aburatani H, Ishikawa S. Immunogenetic Profiling for Gastric Cancers Identifies Sulfated Glycosaminoglycans as Major and Functional B Cell Antigens in Human Malignancies. Cell Rep 2017;20:1073-87. [PMID: 28768193 DOI: 10.1016/j.celrep.2017.07.016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
82 Ishii T, Kawazoe A, Shitara K. Dawn of precision medicine on gastric cancer. Int J Clin Oncol 2019;24:779-88. [PMID: 30976939 DOI: 10.1007/s10147-019-01441-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
83 Yao F, Kausalya JP, Sia YY, Teo AS, Lee WH, Ong AG, Zhang Z, Tan JH, Li G, Bertrand D. Recurrent Fusion Genes in Gastric Cancer: CLDN18-ARHGAP26 Induces Loss of Epithelial Integrity. Cell Rep. 2015;12:272-285. [PMID: 26146084 DOI: 10.1016/j.celrep.2015.06.020] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 9.9] [Reference Citation Analysis]
84 Oze I, Shimada S, Nagasaki H, Akiyama Y, Watanabe M, Yatabe Y, Matsuo K, Yuasa Y. Plasma microRNA-103, microRNA-107, and microRNA-194 levels are not biomarkers for human diffuse gastric cancer. J Cancer Res Clin Oncol. 2017;143:551-554. [PMID: 27909811 DOI: 10.1007/s00432-016-2316-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
85 Ishikawa M, Hayashi H, Sakamoto N, Tanaka S, Nishihara H. Cancer gene profiling explores the possible precision medicine for diffuse-type gastric adenocarcinoma. Med Oncol 2020;37. [DOI: 10.1007/s12032-019-1327-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
86 Xiao D, He J, Guo Z, He H, Yang S, Huang L, Pan H, He J. Rhophilin-2 Upregulates Glutamine Synthetase by Stabilizing c-Myc Protein and Confers Resistance to Glutamine Deprivation in Lung Cancer. Front Oncol 2020;10:571384. [PMID: 33552953 DOI: 10.3389/fonc.2020.571384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Carvajal-carmona LG. Molecular Subtypes and Driver Mutations in Latinos with Gastric Cancer: Implications for Etiological and Translational Research. In: Ramirez AG, Trapido EJ, editors. Advancing the Science of Cancer in Latinos. Cham: Springer International Publishing; 2020. pp. 89-94. [DOI: 10.1007/978-3-030-29286-7_8] [Reference Citation Analysis]
88 Ye XS, Yu C, Aggarwal A, Reinhard C. Genomic alterations and molecular subtypes of gastric cancers in Asians. Chin J Cancer 2016;35:42. [PMID: 27160712 DOI: 10.1186/s40880-016-0106-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
89 Ghadie M, Xia Y. Estimating dispensable content in the human interactome. Nat Commun 2019;10:3205. [PMID: 31324802 DOI: 10.1038/s41467-019-11180-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
90 Leal MF, Wisnieski F, de Oliveira Gigek C, do Santos LC, Calcagno DQ, Burbano RR, Smith MC. What gastric cancer proteomic studies show about gastric carcinogenesis? Tumour Biol. 2016;37:9991-10010. [PMID: 27126070 DOI: 10.1007/s13277-016-5043-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
91 Hugen S, Thomas RE, German AJ, Burgener IA, Mandigers PJJ. Gastric carcinoma in canines and humans, a review. Vet Comp Oncol 2017;15:692-705. [PMID: 27549077 DOI: 10.1111/vco.12249] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
92 Zhang X, Wang Y, Tian T, Zhou G, Jin G. Germline genetic variants were interactively associated with somatic alterations in gastric cancer. Cancer Med 2018;7:3912-20. [PMID: 29923336 DOI: 10.1002/cam4.1612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
93 Wang JL, Ling ZQ. Progress in research of gastric signet ring cell carcinoma. Shijie Huaren Xiaohua Zazhi 2017; 25(4): 358-363 [DOI: 10.11569/wcjd.v25.i4.358] [Reference Citation Analysis]
94 Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017;3:17036. [PMID: 28569272 DOI: 10.1038/nrdp.2017.36] [Cited by in Crossref: 178] [Cited by in F6Publishing: 184] [Article Influence: 35.6] [Reference Citation Analysis]
95 Kataoka K, Ogawa S. Variegated RHOA mutations in human cancers. Experimental Hematology 2016;44:1123-9. [DOI: 10.1016/j.exphem.2016.09.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
96 Chivu-Economescu M, Matei L, Necula LG, Dragu DL, Bleotu C, Diaconu CC. New therapeutic options opened by the molecular classification of gastric cancer. World J Gastroenterol 2018; 24(18): 1942-1961 [PMID: 29760539 DOI: 10.3748/wjg.v24.i18.1942] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
97 Ooki A, Yamaguchi K. The dawn of precision medicine in diffuse-type gastric cancer. Ther Adv Med Oncol 2022;14:175883592210830. [DOI: 10.1177/17588359221083049] [Reference Citation Analysis]
98 Skierucha M, Milne AN, Offerhaus GJA, Polkowski WP, Maciejewski R, Sitarz R. Molecular alterations in gastric cancer with special reference to the early-onset subtype. World J Gastroenterol 2016; 22(8): 2460-2474 [PMID: 26937134 DOI: 10.3748/wjg.v22.i8.2460] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
99 De Rienzo A, Archer MA, Yeap BY, Dao N, Sciaranghella D, Sideris AC, Zheng Y, Holman AG, Wang YE, Dal Cin PS, Fletcher JA, Rubio R, Croft L, Quackenbush J, Sugarbaker PE, Munir KJ, Battilana JR, Gustafson CE, Chirieac LR, Ching SM, Wong J, Tay LC, Rudd S, Hercus R, Sugarbaker DJ, Richards WG, Bueno R. Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma. Cancer Res 2016;76:319-28. [PMID: 26554828 DOI: 10.1158/0008-5472.CAN-15-0751] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
100 Elimova E, Song S, Shimodaira Y, Lin Q, Ajani JA. Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets. Ann Surg Oncol 2016;23:3786-91. [DOI: 10.1245/s10434-016-5428-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
101 Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP. Genomic landscape of cutaneous T cell lymphoma. Nat Genet 2015;47:1011-9. [PMID: 26192916 DOI: 10.1038/ng.3356] [Cited by in Crossref: 220] [Cited by in F6Publishing: 200] [Article Influence: 31.4] [Reference Citation Analysis]
102 Choi YY, Noh SH, Cheong JH. Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives. J Pathol Transl Med. 2016;50:1-9. [PMID: 26498010 DOI: 10.4132/jptm.2015.09.10] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
103 Basturk O, Tan M, Bhanot U, Allen P, Adsay V, Scott SN, Shah R, Berger MF, Askan G, Dikoglu E, Jobanputra V, Wrzeszczynski KO, Sigel C, Iacobuzio-Donahue C, Klimstra DS. The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. Mod Pathol 2016;29:1058-69. [PMID: 27282351 DOI: 10.1038/modpathol.2016.98] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
104 Ge Y, Wu Q, Ma G, Shao W, Liu H, Zhang Q, Xin J, Xue Y, Du M, Zhao Q, Wang M, Chu H, Zhang Z. Hypermethylation of EIF4E promoter is associated with early onset of gastric cancer. Carcinogenesis 2018;39:66-71. [PMID: 29342273 DOI: 10.1093/carcin/bgx110] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
105 Croisé P, Houy S, Gand M, Lanoix J, Calco V, Tóth P, Brunaud L, Lomazzi S, Paramithiotis E, Chelsky D, Ory S, Gasman S. Cdc42 and Rac1 activity is reduced in human pheochromocytoma and correlates with FARP1 and ARHGEF1 expression. Endocr Relat Cancer 2016;23:281-93. [PMID: 26911374 DOI: 10.1530/ERC-15-0502] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
106 Sammarco G, Varricchi G, Ferraro V, Ammendola M, De Fazio M, Altomare DF, Luposella M, Maltese L, Currò G, Marone G, Ranieri G, Memeo R. Mast Cells, Angiogenesis and Lymphangiogenesis in Human Gastric Cancer. Int J Mol Sci 2019;20:E2106. [PMID: 31035644 DOI: 10.3390/ijms20092106] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 17.0] [Reference Citation Analysis]
107 Cortés JR, Palomero T. The curious origins of angioimmunoblastic T-cell lymphoma. Curr Opin Hematol 2016;23:434-43. [PMID: 27177312 DOI: 10.1097/MOH.0000000000000261] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 5.4] [Reference Citation Analysis]
108 Wang Y, Zhao C, Chang L, Jia R, Liu R, Zhang Y, Gao X, Li J, Chen R, Xia X, Bulbul A, Husain H, Guan Y, Yi X, Xu J. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. EBioMedicine. 2019;43:261-269. [PMID: 31031019 DOI: 10.1016/j.ebiom.2019.04.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
109 Tahara T, Shibata T, Okamoto Y, Yamazaki J, Kawamura T, Horiguchi N, Okubo M, Nakano N, Ishizuka T, Nagasaka M, Nakagawa Y, Ohmiya N. Mutation spectrum of TP53 gene predicts clinicopathological features and survival of gastric cancer. Oncotarget 2016;7:42252-60. [PMID: 27323394 DOI: 10.18632/oncotarget.9770] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
110 Chen Y, Cheng WY, Shi H, Huang S, Chen H, Liu D, Xu W, Yu J, Wang J. Classifying gastric cancer using FLORA reveals clinically relevant molecular subtypes and highlights LINC01614 as a biomarker for patient prognosis. Oncogene 2021;40:2898-909. [PMID: 33742127 DOI: 10.1038/s41388-021-01743-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
111 Nanki K, Toshimitsu K, Takano A, Fujii M, Shimokawa M, Ohta Y, Matano M, Seino T, Nishikori S, Ishikawa K, Kawasaki K, Togasaki K, Takahashi S, Sukawa Y, Ishida H, Sugimoto S, Kawakubo H, Kim J, Kitagawa Y, Sekine S, Koo BK, Kanai T, Sato T. Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis. Cell. 2018;174:856-869.e17. [PMID: 30096312 DOI: 10.1016/j.cell.2018.07.027] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 30.7] [Reference Citation Analysis]
112 Ho SWT, Tan P. Dissection of gastric cancer heterogeneity for precision oncology. Cancer Sci 2019;110:3405-14. [PMID: 31495054 DOI: 10.1111/cas.14191] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
113 Nomikou E, Livitsanou M, Stournaras C, Kardassis D. Transcriptional and post-transcriptional regulation of the genes encoding the small GTPases RhoA, RhoB, and RhoC: implications for the pathogenesis of human diseases. Cell Mol Life Sci 2018;75:2111-24. [DOI: 10.1007/s00018-018-2787-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
114 Komura D, Kawabe A, Fukuta K, Sano K, Umezaki T, Koda H, Suzuki R, Tominaga K, Ochi M, Konishi H, Masakado F, Saito N, Sato Y, Onoyama T, Nishida S, Furuya G, Katoh H, Yamashita H, Kakimi K, Seto Y, Ushiku T, Fukayama M, Ishikawa S. Universal encoding of pan-cancer histology by deep texture representations. Cell Rep 2022;38:110424. [PMID: 35235802 DOI: 10.1016/j.celrep.2022.110424] [Reference Citation Analysis]
115 Malik S, Stokes Iii J, Manne U, Singh R, Mishra MK. Understanding the significance of biological clock and its impact on cancer incidence. Cancer Lett 2021;527:80-94. [PMID: 34906624 DOI: 10.1016/j.canlet.2021.12.006] [Reference Citation Analysis]
116 Nelakurti DD, Pappula AL, Rajasekaran S, Miles WO, Petreaca RC. Comprehensive Analysis of MEN1 Mutations and Their Role in Cancer. Cancers (Basel) 2020;12:E2616. [PMID: 32937789 DOI: 10.3390/cancers12092616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
117 Kong R, Yi F, Wen P, Liu J, Chen X, Ren J, Li X, Shang Y, Nie Y, Wu K, Fan D, Zhu L, Feng W, Wu JY. Myo9b is a key player in SLIT/ROBO-mediated lung tumor suppression. J Clin Invest 2015;125:4407-20. [PMID: 26529257 DOI: 10.1172/JCI81673] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 4.9] [Reference Citation Analysis]
118 Lee J, Cristescu R, Kim KM, Kim K, Kim ST, Park SH, Kang WK. Development of mesenchymal subtype gene signature for clinical application in gastric cancer. Oncotarget. 2017;8:66305-66315. [PMID: 29029513 DOI: 10.18632/oncotarget.19985] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
119 Nishizawa T, Nakano K, Harada A, Kakiuchi M, Funahashi SI, Suzuki M, Ishikawa S, Aburatani H. DGC-specific RHOA mutations maintained cancer cell survival and promoted cell migration via ROCK inactivation. Oncotarget 2018;9:23198-207. [PMID: 29796182 DOI: 10.18632/oncotarget.25269] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
120 Ansari S, Gantuya B, Tuan VP, Yamaoka Y. Diffuse Gastric Cancer: A Summary of Analogous Contributing Factors for Its Molecular Pathogenicity. Int J Mol Sci 2018;19:E2424. [PMID: 30115886 DOI: 10.3390/ijms19082424] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
121 Nomura M, Mukasa A, Nagae G, Yamamoto S, Tatsuno K, Ueda H, Fukuda S, Umeda T, Suzuki T, Otani R, Kobayashi K, Maruyama T, Tanaka S, Takayanagi S, Nejo T, Takahashi S, Ichimura K, Nakamura T, Muragaki Y, Narita Y, Nagane M, Ueki K, Nishikawa R, Shibahara J, Aburatani H, Saito N. Distinct molecular profile of diffuse cerebellar gliomas. Acta Neuropathol 2017;134:941-56. [PMID: 28852847 DOI: 10.1007/s00401-017-1771-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
122 Kumagai S, Togashi Y, Sakai C, Kawazoe A, Kawazu M, Ueno T, Sato E, Kuwata T, Kinoshita T, Yamamoto M, Nomura S, Tsukamoto T, Mano H, Shitara K, Nishikawa H. An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. Immunity 2020;53:187-203.e8. [PMID: 32640259 DOI: 10.1016/j.immuni.2020.06.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
123 Li S, Mao Q, Zhang Z, Wang Y, Chen D, Chen Z, Lu J, Alatas B. Identification of a Five-Gene Panel to Assess Prognosis for Gastric Cancer. BioMed Research International 2022;2022:1-9. [DOI: 10.1155/2022/5593619] [Reference Citation Analysis]
124 Sai E, Miwa Y, Takeyama R, Kojima S, Ueno T, Yashiro M, Seto Y, Mano H. Identification of candidates for driver oncogenes in scirrhous-type gastric cancer cell lines. Cancer Sci 2019;110:2643-51. [PMID: 31222839 DOI: 10.1111/cas.14111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
125 Kalailingam P, Tan HB, Pan JY, Tan SH, Thanabalu T. Overexpression of CDC42SE1 in A431 Cells Reduced Cell Proliferation by Inhibiting the Akt Pathway. Cells 2019;8:E117. [PMID: 30717410 DOI: 10.3390/cells8020117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
126 Chen C, Zhou Q, Wu R, Li B, Chen Q, Zhang X, Shi C. A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets. Biomed Res Int 2019;2019:2183510. [PMID: 31781598 DOI: 10.1155/2019/2183510] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
127 Pizzi MP, Bartelli TF, Pelosof AG, Freitas HC, Begnami MD, de Abrantes LLS, Sztokfisz C, Valieris R, Knebel FH, Coelho LGV, da Costa WL, Coimbra FJF, da Silva IT, de Amorim MG, Nunes DN, Dias-Neto E. Identification of DNA mutations in gastric washes from gastric adenocarcinoma patients: Possible implications for liquid biopsies and patient follow-up. Int J Cancer. 2019;. [PMID: 30779121 DOI: 10.1002/ijc.32217] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
128 Bueno De Paiva L, Aline Bernusso V, Machado-Neto JA, Traina F, Ridley AJ, Olalla-Saad ST, Lazarini M. Effects of RhoA and RhoC upon the sensitivity of prostate cancer cells to glutamine deprivation. Small GTPases 2021;12:20-6. [PMID: 30449238 DOI: 10.1080/21541248.2018.1546098] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
129 Ishikawa S. Opposite RHOA functions within the ATLL category. Blood 2016;127:524-5. [PMID: 26847067 DOI: 10.1182/blood-2015-12-683458] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
130 Rokutan H, Hosoda F, Hama N, Nakamura H, Totoki Y, Furukawa E, Arakawa E, Ohashi S, Urushidate T, Satoh H, Shimizu H, Igarashi K, Yachida S, Katai H, Taniguchi H, Fukayama M, Shibata T. Comprehensive mutation profiling of mucinous gastric carcinoma: Somatic mutations in mucinous gastric carcinoma. J Pathol 2016;240:137-48. [DOI: 10.1002/path.4761] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
131 Aihara K, Mukasa A, Nagae G, Nomura M, Yamamoto S, Ueda H, Tatsuno K, Shibahara J, Takahashi M, Momose T, Tanaka S, Takayanagi S, Yanagisawa S, Nejo T, Takahashi S, Omata M, Otani R, Saito K, Narita Y, Nagane M, Nishikawa R, Ueki K, Aburatani H, Saito N. Genetic and epigenetic stability of oligodendrogliomas at recurrence. Acta Neuropathol Commun 2017;5:18. [PMID: 28270234 DOI: 10.1186/s40478-017-0422-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
132 Xu Y, Xue D, Bankhead A 3rd, Neamati N. Why All the Fuss about Oxidative Phosphorylation (OXPHOS)? J Med Chem 2020;63:14276-307. [PMID: 33103432 DOI: 10.1021/acs.jmedchem.0c01013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
133 Kinoshita H, Hayakawa Y, Koike K. Metaplasia in the Stomach-Precursor of Gastric Cancer? Int J Mol Sci. 2017;18:pii: E2063. [PMID: 28953255 DOI: 10.3390/ijms18102063] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
134 Cheng X, Yu S, Wang Y, Cui Y, Li W, Yu Y, Tang C, Jiang H, Ji Y, Sun Y, Wang X, Shen Z, Liu F, Liu TS. The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study. Gastric Cancer 2019;22:587-97. [PMID: 30426294 DOI: 10.1007/s10120-018-0895-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
135 Zhao Y, Feng F, Zhou YN. Stem cells in gastric cancer. World J Gastroenterol 2015; 21(1): 112-123 [PMID: 25574084 DOI: 10.3748/wjg.v21.i1.112] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
136 Schipper K, Seinstra D, Paulien Drenth A, van der Burg E, Ramovs V, Sonnenberg A, van Rheenen J, Nethe M, Jonkers J. Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin. Nat Commun 2019;10:3800. [PMID: 31444332 DOI: 10.1038/s41467-019-11716-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
137 Stevers M, Rabban JT, Garg K, Van Ziffle J, Onodera C, Grenert JP, Yeh I, Bastian BC, Zaloudek C, Solomon DA. Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42. Mod Pathol 2019;32:88-99. [PMID: 30171198 DOI: 10.1038/s41379-018-0127-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
138 Kwon CH, Kim YK, Lee S, Kim A, Park HJ, Choi Y, Won YJ, Park DY, Lauwers GY. Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes. Histopathology 2018;72:556-68. [PMID: 28873240 DOI: 10.1111/his.13383] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
139 Takeshima H, Niwa T, Takahashi T, Wakabayashi M, Yamashita S, Ando T, Inagawa Y, Taniguchi H, Katai H, Sugiyama T, Kiyono T, Ushijima T. Frequent involvement of chromatin remodeler alterations in gastric field cancerization. Cancer Lett 2015;357:328-38. [PMID: 25462860 DOI: 10.1016/j.canlet.2014.11.038] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
140 Lawson CD, Fan C, Mitin N, Baker NM, George SD, Graham DM, Perou CM, Burridge K, Der CJ, Rossman KL. Rho GTPase Transcriptome Analysis Reveals Oncogenic Roles for Rho GTPase-Activating Proteins in Basal-like Breast Cancers. Cancer Res 2016;76:3826-37. [PMID: 27216196 DOI: 10.1158/0008-5472.CAN-15-2923] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
141 Chen F, Wang Y, Rafikov R, Haigh S, Zhi WB, Kumar S, Doulias PT, Rafikova O, Pillich H, Chakraborty T, Lucas R, Verin AD, Catravas JD, She JX, Black SM, Fulton DJR. RhoA S-nitrosylation as a regulatory mechanism influencing endothelial barrier function in response to G+-bacterial toxins. Biochem Pharmacol 2017;127:34-45. [PMID: 28017778 DOI: 10.1016/j.bcp.2016.12.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
142 Long M, Simpson JC. Rho GTPases operating at the Golgi complex: Implications for membrane traffic and cancer biology. Tissue Cell 2017;49:163-9. [PMID: 27720426 DOI: 10.1016/j.tice.2016.09.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
143 Iyer P, Moslim M, Farma JM, Denlinger CS. Diffuse gastric cancer: histologic, molecular, and genetic basis of disease. Transl Gastroenterol Hepatol 2020;5:52. [PMID: 33073047 DOI: 10.21037/tgh.2020.01.02] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
144 Min B, Hwang J, Kim NK, Park G, Kang SY, Ahn S, Ahn S, Ha SY, Lee YK, Kushima R, Van Vrancken M, Kim MJ, Park C, Park HY, Chae J, Jang SS, Kim SJ, Kim Y, Kim J, Kim K. Dysregulated Wnt signalling and recurrent mutations of the tumour suppressor RNF43 in early gastric carcinogenesis: Wnt signalling and RNF43 mutation in early gastric carcinogenesis. J Pathol 2016;240:304-14. [DOI: 10.1002/path.4777] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
145 Chen P, Chen G, Wang C, Mao C. RAB13 as a novel prognosis marker promotes proliferation and chemotherapeutic resistance in gastric cancer. Biochem Biophys Res Commun 2019;519:113-20. [PMID: 31474334 DOI: 10.1016/j.bbrc.2019.08.141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
146 Kim JG, Islam R, Cho JY, Jeong H, Cap KC, Park Y, Hossain AJ, Park JB. Regulation of RhoA GTPase and various transcription factors in the RhoA pathway. J Cell Physiol 2018;233:6381-92. [PMID: 29377108 DOI: 10.1002/jcp.26487] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 9.5] [Reference Citation Analysis]
147 Park H, Cho SY, Kim H, Na D, Han JY, Chae J, Park C, Park OK, Min S, Kang J, Choi B, Min J, Kwon JY, Suh YS, Kong SH, Lee HJ, Liu ET, Kim JI, Kim S, Yang HK, Lee C. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. Proc Natl Acad Sci U S A 2015;112:12492-7. [PMID: 26401016 DOI: 10.1073/pnas.1507491112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
148 Mun DG, Bhin J, Kim S, Kim H, Jung JH, Jung Y, Jang YE, Park JM, Kim H, Jung Y, Lee H, Bae J, Back S, Kim SJ, Kim J, Park H, Li H, Hwang KB, Park YS, Yook JH, Kim BS, Kwon SY, Ryu SW, Park DY, Jeon TY, Kim DH, Lee JH, Han SU, Song KS, Park D, Park JW, Rodriguez H, Kim J, Lee H, Kim KP, Yang EG, Kim HK, Paek E, Lee S, Lee SW, Hwang D. Proteogenomic Characterization of Human Early-Onset Gastric Cancer. Cancer Cell 2019;35:111-124.e10. [PMID: 30645970 DOI: 10.1016/j.ccell.2018.12.003] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 22.3] [Reference Citation Analysis]
149 Yan HHN, Siu HC, Law S, Ho SL, Yue SSK, Tsui WY, Chan D, Chan AS, Ma S, Lam KO, Bartfeld S, Man AHY, Lee BCH, Chan ASY, Wong JWH, Cheng PSW, Chan AKW, Zhang J, Shi J, Fan X, Kwong DLW, Mak TW, Yuen ST, Clevers H, Leung SY. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening. Cell Stem Cell. 2018;23:882-897.e11. [PMID: 30344100 DOI: 10.1016/j.stem.2018.09.016] [Cited by in Crossref: 145] [Cited by in F6Publishing: 152] [Article Influence: 36.3] [Reference Citation Analysis]
150 Uchida K, Tanaka Y, Ichikawa H, Watanabe M, Mitani S, Morita K, Fujii H, Ishikawa M, Yoshino G, Okinaga H, Nagae G, Aburatani H, Ikeda Y, Susa T, Tamamori-Adachi M, Fukusato T, Uozaki H, Okazaki T, Iizuka M. An Excess of CYP24A1, Lack of CaSR, and a Novel lncRNA Near the PTH Gene Characterize an Ectopic PTH-Producing Tumor. J Endocr Soc 2017;1:691-711. [PMID: 29264523 DOI: 10.1210/js.2017-00063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
151 Sugiyama Y, Gotoh O, Fukui N, Tanaka N, Hasumi K, Takazawa Y, Noda T, Mori S. Two Distinct Tumorigenic Processes in Endometrial Endometrioid Adenocarcinoma. The American Journal of Pathology 2020;190:234-51. [DOI: 10.1016/j.ajpath.2019.09.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
152 Fioroni I, Dell'Aquila E, Pantano F, Intagliata S, Caricato M, Vincenzi B, Coppola R, Santini D, Tonini G. Role of c-mesenchymal-epithelial transition pathway in gastric cancer. Expert Opin Pharmacother 2015;16:1195-207. [PMID: 25881479 DOI: 10.1517/14656566.2015.1037739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
153 Haga RB, Ridley AJ. Rho GTPases: Regulation and roles in cancer cell biology. Small GTPases 2016;7:207-21. [PMID: 27628050 DOI: 10.1080/21541248.2016.1232583] [Cited by in Crossref: 165] [Cited by in F6Publishing: 159] [Article Influence: 27.5] [Reference Citation Analysis]
154 Hirotsu Y, Mochizuki H, Amemiya K, Ohyama H, Yoshimura D, Amano H, Miura Y, Ashizawa H, Nakagomi K, Takaoka S, Hosoda K, Suzuki Y, Oyama T, Hada M, Kojima Y, Omata M. Deficiency of mismatch repair genes is less frequently observed in signet ring cell compared with non-signet ring cell gastric cancer. Med Oncol 2019;36:23. [PMID: 30694393 DOI: 10.1007/s12032-019-1246-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
155 Chia NY, Tan P. Molecular classification of gastric cancer. Ann Oncol. 2016;27:763-769. [PMID: 26861606 DOI: 10.1093/annonc/mdw040] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 12.2] [Reference Citation Analysis]
156 Jansen S, Gosens R, Wieland T, Schmidt M. Paving the Rho in cancer metastasis: Rho GTPases and beyond. Pharmacol Ther 2018;183:1-21. [PMID: 28911825 DOI: 10.1016/j.pharmthera.2017.09.002] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 14.8] [Reference Citation Analysis]
157 Chao J, Lee J, Klempner SJ. Moving molecular subtypes to the clinic in gastric cancer. Transl Cancer Res 2016;5:S25-30. [PMID: 28781963 DOI: 10.21037/tcr.2016.05.21] [Reference Citation Analysis]
158 Oya Y, Hayakawa Y, Koike K. Tumor microenvironment in gastric cancers. Cancer Sci 2020;111:2696-707. [PMID: 32519436 DOI: 10.1111/cas.14521] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
159 Bhaskar Rao D, Devanandan HJ, Ganesan K. Identification of kinases and kinase inhibitors for the differential targeting of Wnt/β-catenin signaling in gastric cancer subtypes. Drug Dev Res 2021. [PMID: 34002415 DOI: 10.1002/ddr.21833] [Reference Citation Analysis]
160 Ruggiero C, Lalli E. Targeting the cytoskeleton against metastatic dissemination. Cancer Metastasis Rev 2021;40:89-140. [PMID: 33471283 DOI: 10.1007/s10555-020-09936-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
161 Ikari N, Serizawa A, Tanji E, Yamamoto M, Furukawa T. Analysis of RHOA mutations and their significance in the proliferation and transcriptome of digestive tract cancer cells. Oncol Lett 2021;22:735. [PMID: 34466148 DOI: 10.3892/ol.2021.12996] [Reference Citation Analysis]
162 Takeda H, Rust AG, Ward JM, Yew CC, Jenkins NA, Copeland NG. Sleeping Beauty transposon mutagenesis identifies genes that cooperate with mutant Smad4 in gastric cancer development. Proc Natl Acad Sci U S A. 2016;113:E2057-E2065. [PMID: 27006499 DOI: 10.1073/pnas.1603223113] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
163 Liu D, Sun L, Tong J, Chen X, Li H, Zhang Q. Prognostic significance of glutathione peroxidase 2 in gastric carcinoma. Tumour Biol 2017;39:1010428317701443. [PMID: 28631563 DOI: 10.1177/1010428317701443] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
164 Decourtye-Espiard L, Bougen-Zhukov N, Godwin T, Brew T, Schulpen E, Black MA, Guilford P. E-Cadherin-Deficient Epithelial Cells Are Sensitive to HDAC Inhibitors. Cancers (Basel) 2021;14:175. [PMID: 35008338 DOI: 10.3390/cancers14010175] [Reference Citation Analysis]
165 Te Boekhorst V, Friedl P. Plasticity of Cancer Cell Invasion-Mechanisms and Implications for Therapy. Adv Cancer Res 2016;132:209-64. [PMID: 27613134 DOI: 10.1016/bs.acr.2016.07.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
166 Zhao ZT, Li Y, Yuan HY, Ma FH, Song YM, Tian YT. Identification of key genes and pathways in gastric signet ring cell carcinoma based on transcriptome analysis. World J Clin Cases 2020; 8(4): 658-669 [PMID: 32149050 DOI: 10.12998/wjcc.v8.i4.658] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
167 Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Ann Oncol 2017;28:128-35. [PMID: 28177460 DOI: 10.1093/annonc/mdw434] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
168 Nagata Y, Kontani K, Enami T, Kataoka K, Ishii R, Totoki Y, Kataoka TR, Hirata M, Aoki K, Nakano K, Kitanaka A, Sakata-yanagimoto M, Egami S, Shiraishi Y, Chiba K, Tanaka H, Shiozawa Y, Yoshizato T, Suzuki H, Kon A, Yoshida K, Sato Y, Sato-otsubo A, Sanada M, Munakata W, Nakamura H, Hama N, Miyano S, Nureki O, Shibata T, Haga H, Shimoda K, Katada T, Chiba S, Watanabe T, Ogawa S. Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood 2016;127:596-604. [DOI: 10.1182/blood-2015-06-644948] [Reference Citation Analysis]
169 Matsushita H, Hasegawa K, Oda K, Yamamoto S, Asada K, Karasaki T, Yabuno A, Nishijima A, Nejo T, Kobayashi Y, Sato S, Ikeda Y, Miyai M, Takahashi Y, Yamaguchi R, Fujiwara K, Aburatani H, Kakimi K. Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma. J Immunother Cancer 2020;8:e000375. [PMID: 32461346 DOI: 10.1136/jitc-2019-000375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
170 Smith A, Piga I, Galli M, Stella M, Denti V, Del Puppo M, Magni F. Matrix-Assisted Laser Desorption/Ionisation Mass Spectrometry Imaging in the Study of Gastric Cancer: A Mini Review. Int J Mol Sci 2017;18:E2588. [PMID: 29194417 DOI: 10.3390/ijms18122588] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
171 Rubinstein JC, Nicolson NG, Ahuja N. Next-generation Sequencing in the Management of Gastric and Esophageal Cancers. Surg Clin North Am 2019;99:511-27. [PMID: 31047039 DOI: 10.1016/j.suc.2019.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
172 Milewska M, Cremona M, Morgan C, O'Shea J, Carr A, Vellanki SH, Hopkins AM, Toomey S, Madden SF, Hennessy BT, Eustace AJ. Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. Ther Adv Med Oncol 2018;10:1758834017746040. [PMID: 29383036 DOI: 10.1177/1758834017746040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
173 Rugge M, Fassan M, Graham DY. Epidemiology of Gastric Cancer. In: Strong VE, editor. Gastric Cancer. Cham: Springer International Publishing; 2015. pp. 23-34. [DOI: 10.1007/978-3-319-15826-6_2] [Cited by in Crossref: 68] [Cited by in F6Publishing: 17] [Article Influence: 9.7] [Reference Citation Analysis]
174 Matsushita H, Hasegawa K, Oda K, Yamamoto S, Nishijima A, Imai Y, Asada K, Ikeda Y, Karasaki T, Fujiwara K, Aburatani H, Kakimi K. The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma. Oncoimmunology 2017;6:e1338996. [PMID: 28920005 DOI: 10.1080/2162402X.2017.1338996] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
175 Nowak KM, Chetty R. SWI/SNF-deficient cancers of the Gastroenteropancreatic tract: an in-depth review of the literature and pathology. Semin Diagn Pathol 2021;38:195-8. [PMID: 33288347 DOI: 10.1053/j.semdp.2020.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
176 Yoon C, Cho SJ, Aksoy BA, Park DJ, Schultz N, Ryeom SW, Yoon SS. Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells. Clin Cancer Res 2016;22:971-83. [PMID: 26482039 DOI: 10.1158/1078-0432.CCR-15-1356] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 7.7] [Reference Citation Analysis]
177 Bornschein J, Kupcinskas J. Recent progress in the understanding of gastric cancer - Do patients experience a benefit yet? Best Pract Res Clin Gastroenterol 2021;50-51:101740. [PMID: 33975678 DOI: 10.1016/j.bpg.2021.101740] [Reference Citation Analysis]
178 Hirotsu Y, Kojima Y, Okimoto K, Amemiya K, Mochizuki H, Omata M. Comparison between two amplicon-based sequencing panels of different scales in the detection of somatic mutations associated with gastric cancer. BMC Genomics 2016;17:833. [PMID: 27782820 DOI: 10.1186/s12864-016-3166-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
179 Shin SY, Kim JH, Chun J, Yoon YH, Park H. Chronic atrophic gastritis and intestinal metaplasia surrounding diffuse-type gastric cancer: Are they just bystanders in the process of carcinogenesis? PLoS One 2019;14:e0226427. [PMID: 31851694 DOI: 10.1371/journal.pone.0226427] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
180 Gilbert-Ross M, Marcus AI, Zhou W. RhoA, a novel tumor suppressor or oncogene as a therapeutic target? Genes Dis 2015;2:2-3. [PMID: 26114154 DOI: 10.1016/j.gendis.2014.10.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
181 Cho J, Ahn S, Son DS, Kim NK, Lee KW, Kim S, Lee J, Park SH, Park JO, Kang WK, An JY, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Kim KM. Bridging genomics and phenomics of gastric carcinoma. Int J Cancer 2019;145:2407-17. [PMID: 30801717 DOI: 10.1002/ijc.32228] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
182 Inokuchi M, Fujimori Y, Otsuki S, Sato Y, Nakagawa M, Kojima K. Therapeutic targeting of fibroblast growth factor receptors in gastric cancer. Gastroenterol Res Pract. 2015;2015:796380. [PMID: 26000013 DOI: 10.1155/2015/796380] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
183 Li M, Rao X, Cui Y, Zhang L, Li X, Wang B, Zheng Y, Teng L, Zhou T, Zhuo W. The keratin 17/YAP/IL6 axis contributes to E-cadherin loss and aggressiveness of diffuse gastric cancer. Oncogene 2021. [PMID: 34845376 DOI: 10.1038/s41388-021-02119-3] [Reference Citation Analysis]
184 Zhou F, Shi J, Fang C, Zou X, Huang Q. Gastric Carcinomas in Young (Younger than 40 Years) Chinese Patients: Clinicopathology, Family History, and Postresection Survival. Medicine (Baltimore) 2016;95:e2873. [PMID: 26945372 DOI: 10.1097/MD.0000000000002873] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
185 Kim J, Choi K, Hong C, Park H, Choi E, Kim Y, Park J. Tyr42 phosphorylation of RhoA GTPase promotes tumorigenesis through nuclear factor (NF)-κB. Free Radical Biology and Medicine 2017;112:69-83. [DOI: 10.1016/j.freeradbiomed.2017.07.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
186 Li Y, Wang Y, Li D, Zhang Y, Zhao T, Li C. Procaine is a specific DNA methylation inhibitor with anti‐tumor effect for human gastric cancer. J Cell Biochem 2018;119:2440-9. [DOI: 10.1002/jcb.26407] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
187 Phesse T, Flanagan D, Vincan E. Frizzled7: A Promising Achilles' Heel for Targeting the Wnt Receptor Complex to Treat Cancer. Cancers (Basel) 2016;8:E50. [PMID: 27196929 DOI: 10.3390/cancers8050050] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 7.8] [Reference Citation Analysis]
188 Al Saqri A, Malgundkar SH, Al Kindi F, Gupta I, Al Moundhri M, Tamimi Y. SOCS3 gene silencing does not occur through methylation and mutations in gastric cancer. Hum Cell 2022. [PMID: 35596898 DOI: 10.1007/s13577-022-00715-3] [Reference Citation Analysis]
189 Miyamoto S, Nagamura Y, Nakabo A, Okabe A, Yanagihara K, Fukami K, Sakai R, Yamaguchi H. Aberrant alternative splicing of RHOA is associated with loss of its expression and activity in diffuse-type gastric carcinoma cells. Biochem Biophys Res Commun 2018;495:1942-7. [PMID: 29247652 DOI: 10.1016/j.bbrc.2017.12.067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
190 Kaida T, Nitta H, Kitano Y, Yamamura K, Arima K, Izumi D, Higashi T, Kurashige J, Imai K, Hayashi H, Iwatsuki M, Ishimoto T, Hashimoto D, Yamashita Y, Chikamoto A, Imanura T, Ishiko T, Beppu T, Baba H. C5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA. Oncotarget 2016;7:84798-809. [PMID: 27756879 DOI: 10.18632/oncotarget.12656] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
191 Shimada S, Akiyama Y, Mogushi K, Ishigami-Yuasa M, Kagechika H, Nagasaki H, Fukamachi H, Yuasa Y, Tanaka S. Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models. Br J Cancer 2018;118:972-84. [PMID: 29527007 DOI: 10.1038/s41416-018-0008-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
192 Futami T, Kawase T, Mori K, Asaumi M, Kihara R, Shindoh N, Kuromitsu S. Identification of a novel oncogenic mutation of FGFR4 in gastric cancer. Sci Rep 2019;9:14627. [PMID: 31601997 DOI: 10.1038/s41598-019-51217-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
193 Liu J, Li S, Chen S, Chen S, Geng Q, Xu D. c‐Met‐dependent phosphorylation of RhoA plays a key role in gastric cancer tumorigenesis. J Pathol 2019;249:126-36. [DOI: 10.1002/path.5287] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
194 Liu X, Meltzer SJ. Gastric Cancer in the Era of Precision Medicine. Cell Mol Gastroenterol Hepatol 2017;3:348-58. [PMID: 28462377 DOI: 10.1016/j.jcmgh.2017.02.003] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 11.4] [Reference Citation Analysis]
195 Gen Y, Yasui K, Kitaichi T, Iwai N, Terasaki K, Dohi O, Hashimoto H, Fukui H, Inada Y, Fukui A, Jo M, Moriguchi M, Nishikawa T, Umemura A, Yamaguchi K, Konishi H, Naito Y, Itoh Y. ASPP2 suppresses invasion and TGF-β1-induced epithelial-mesenchymal transition by inhibiting Smad7 degradation mediated by E3 ubiquitin ligase ITCH in gastric cancer. Cancer Lett 2017;398:52-61. [PMID: 28400336 DOI: 10.1016/j.canlet.2017.04.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
196 Norollahi SE, Mansour-Ghanaei F, Joukar F, Ghadarjani S, Mojtahedi K, Gharaei Nejad K, Hemmati H, Gharibpoor F, Khaksar R, Samadani AA. Therapeutic approach of Cancer stem cells (CSCs) in gastric adenocarcinoma; DNA methyltransferases enzymes in cancer targeted therapy. Biomed Pharmacother. 2019;115:108958. [PMID: 31075731 DOI: 10.1016/j.biopha.2019.108958] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
197 Wen KW, Grenert JP, Joseph NM, Shafizadeh N, Huang A, Hosseini M, Kakar S. Genomic profile of appendiceal goblet cell carcinoid is distinct compared to appendiceal neuroendocrine tumor and conventional adenocarcinoma. Hum Pathol 2018;77:166-74. [PMID: 29634977 DOI: 10.1016/j.humpath.2018.03.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
198 Kim Y, Cho MY, Kim J, Kim SN, Oh SC, Lee KA. Profiling cancer-associated genetic alterations and molecular classification of cancer in Korean gastric cancer patients. Oncotarget 2017;8:69888-905. [PMID: 29050249 DOI: 10.18632/oncotarget.19435] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
199 Fontana E, Smyth EC. Novel targets in the treatment of advanced gastric cancer: a perspective review. Ther Adv Med Oncol. 2016;8:113-125. [PMID: 26929787 DOI: 10.1177/1758834015616935] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
200 Huang X, Huang K, Johnson T, Radovich M, Zhang J, Ma J, Wang Y. ParsVNN: parsimony visible neural networks for uncovering cancer-specific and drug-sensitive genes and pathways. NAR Genom Bioinform 2021;3:lqab097. [PMID: 34729476 DOI: 10.1093/nargab/lqab097] [Reference Citation Analysis]
201 Sun Z, Zhang H, Zhang Y, Liao L, Zhou W, Zhang F, Lian F, Huang J, Xu P, Zhang R, Lu W, Zhu M, Tao H, Yang F, Ding H, Chen S, Yue L, Zhou B, Zhang N, Tan M, Jiang H, Chen K, Liu B, Liu C, Dang Y, Luo C. Covalent Inhibitors Allosterically Block the Activation of Rho Family Proteins and Suppress Cancer Cell Invasion. Adv Sci (Weinh) 2020;7:2000098. [PMID: 32714746 DOI: 10.1002/advs.202000098] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
202 Sun Y, Yu W, Guan W, Cai L, Qiao M, Zheng L, Jiang R, Wang R, Wang L. Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer. Cancer Manag Res 2019;11:6397-410. [PMID: 31372044 DOI: 10.2147/CMAR.S206189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
203 Lens SMA, Medema RH. Cytokinesis defects and cancer. Nat Rev Cancer 2019;19:32-45. [DOI: 10.1038/s41568-018-0084-6] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 19.0] [Reference Citation Analysis]
204 García-Mariscal A, Li H, Pedersen E, Peyrollier K, Ryan KM, Stanley A, Quondamatteo F, Brakebusch C. Loss of RhoA promotes skin tumor formation and invasion by upregulation of RhoB. Oncogene 2018;37:847-60. [PMID: 29059167 DOI: 10.1038/onc.2017.333] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
205 Shimizu T, Chiba T, Marusawa H. Helicobacter pylori-Mediated Genetic Instability and Gastric Carcinogenesis. Curr Top Microbiol Immunol. 2017;400:305-323. [PMID: 28124159 DOI: 10.1007/978-3-319-50520-6_13] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
206 Garattini SK, Basile D, Cattaneo M, Fanotto V, Ongaro E, Bonotto M, Negri FV, Berenato R, Ermacora P, Cardellino GG, Giovannoni M, Pella N, Scartozzi M, Antonuzzo L, Silvestris N, Fasola G, Aprile G. Molecular classifications of gastric cancers: Novel insights and possible future applications. World J Gastrointest Oncol 2017; 9(5): 194-208 [PMID: 28567184 DOI: 10.4251/wjgo.v9.i5.194] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
207 Narumiya S, Thumkeo D. Rho signaling research: history, current status and future directions. FEBS Lett 2018;592:1763-76. [PMID: 29749605 DOI: 10.1002/1873-3468.13087] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 15.3] [Reference Citation Analysis]
208 Suzuki A, Katoh H, Komura D, Kakiuchi M, Tagashira A, Yamamoto S, Tatsuno K, Ueda H, Nagae G, Fukuda S, Umeda T, Totoki Y, Abe H, Ushiku T, Matsuura T, Sakai E, Ohshima T, Nomura S, Seto Y, Shibata T, Rino Y, Nakajima A, Fukayama M, Ishikawa S, Aburatani H. Defined lifestyle and germline factors predispose Asian populations to gastric cancer. Sci Adv. 2020;6:eaav9778. [PMID: 32426482 DOI: 10.1126/sciadv.aav9778] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
209 Ye W, Li Y, Fan L, Zhao Q, Yuan H, Tan B, Zhang Z. Effect of annexin A7 suppression on the apoptosis of gastric cancer cells. Mol Cell Biochem 2017;429:33-43. [PMID: 28176245 DOI: 10.1007/s11010-016-2934-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
210 Fujisawa M, Chiba S, Sakata-Yanagimoto M. Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma. J Clin Exp Hematop 2017;57:109-19. [PMID: 29279549 DOI: 10.3960/jslrt.17019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
211 Lim B, Kim JH, Kim M, Kim SY. Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer. World J Gastroenterol 2016; 22(3): 1190-1201 [PMID: 26811657 DOI: 10.3748/wjg.v22.i3.1190] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
212 Shimizu T, Marusawa H, Watanabe N, Chiba T. Molecular Pathogenesis of Helicobacter pylori-Related Gastric Cancer. Gastroenterol Clin North Am. 2015;44:625-638. [PMID: 26314672 DOI: 10.1016/j.gtc.2015.05.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
213 Monster JL, Kemp LJS, Gloerich M, van der Post RS. Diffuse gastric cancer: Emerging mechanisms of tumor initiation and progression. Biochim Biophys Acta Rev Cancer 2022;:188719. [PMID: 35307354 DOI: 10.1016/j.bbcan.2022.188719] [Reference Citation Analysis]
214 Maeda M, Ushijima T. RHOA mutation may be associated with diffuse-type gastric cancer progression, but is it gain or loss? Gastric Cancer 2016;19:326-8. [DOI: 10.1007/s10120-015-0525-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
215 Ravegnini G, Fosso B, Saverio VD, Sammarini G, Zanotti F, Rossi G, Ricci M, D'Amico F, Valori G, Ioli A, Turroni S, Brigidi P, Hrelia P, Angelini S. Gastric Adenocarcinomas and Signet-Ring Cell Carcinoma: Unraveling Gastric Cancer Complexity through Microbiome Analysis-Deepening Heterogeneity for a Personalized Therapy. Int J Mol Sci 2020;21:E9735. [PMID: 33419357 DOI: 10.3390/ijms21249735] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
216 Fukumoto K, Nguyen TB, Chiba S, Sakata-Yanagimoto M. Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma. Cancer Sci 2018;109:490-6. [PMID: 28889481 DOI: 10.1111/cas.13393] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
217 Kim J, Kwon H, Wu G, Park Y, Lee J, Kim J, Kim S, Choe M, Kang SG, Seo G, Kim P, Park J. RhoA GTPase oxidation stimulates cell proliferation via nuclear factor-κB activation. Free Radical Biology and Medicine 2017;103:57-68. [DOI: 10.1016/j.freeradbiomed.2016.12.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
218 Rugge M, Capelle LG, Fassan M. Individual risk stratification of gastric cancer: evolving concepts and their impact on clinical practice. Best Pract Res Clin Gastroenterol. 2014;28:1043-1053. [PMID: 25439070 DOI: 10.1016/j.bpg.2014.09.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
219 Díaz Del Arco C, Estrada Muñoz L, Molina Roldán E, Cerón Nieto MÁ, Ortega Medina L, García Gómez de Las Heras S, Fernández Aceñero MJ. Immunohistochemical classification of gastric cancer based on new molecular biomarkers: a potential predictor of survival. Virchows Arch 2018;473:687-95. [PMID: 30140949 DOI: 10.1007/s00428-018-2443-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
220 Wang D, Qian X, Sanchez-Solana B, Tripathi BK, Durkin ME, Lowy DR. Cancer-Associated Point Mutations in the DLC1 Tumor Suppressor and Other Rho-GAPs Occur Frequently and Are Associated with Decreased Function. Cancer Res 2020;80:3568-79. [PMID: 32606003 DOI: 10.1158/0008-5472.CAN-19-3984] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
221 Elimova E, Mizrak Kaya D, Harada K, Ajani JA. Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clin Proc 2016;91:1307-18. [PMID: 27594190 DOI: 10.1016/j.mayocp.2016.07.018] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
222 Kowalczyk M, Kamps D, Wu Y, Dehmelt L, Nalbant P. Monitoring the Response of Multiple Signal Network Components to Acute Chemo-Optogenetic Perturbations in Living Cells. Chembiochem 2021;:e202100582. [PMID: 34897929 DOI: 10.1002/cbic.202100582] [Reference Citation Analysis]
223 Biagioni A, Staderini F, Peri S, Versienti G, Schiavone N, Cianchi F, Papucci L, Magnelli L. 5-Fluorouracil Conversion Pathway Mutations in Gastric Cancer. Biology (Basel). 2020;9. [PMID: 32887417 DOI: 10.3390/biology9090265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
224 Jamshidi F, Nielsen TO, Huntsman DG. Cancer genomics: why rare is valuable. J Mol Med (Berl). 2015;93:369-381. [PMID: 25676695 DOI: 10.1007/s00109-015-1260-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
225 Kawazoe A, Shitara K. Next-generation sequencing and biomarkers for gastric cancer: what is the future? Ther Adv Med Oncol 2019;11:1758835919848189. [PMID: 31258627 DOI: 10.1177/1758835919848189] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
226 Nishizawa T, Nakano K, Fujii E, Komura D, Kuroiwa Y, Ishimaru C, Monnai M, Aburatani H, Ishikawa S, Suzuki M. In vivo effects of mutant RHOA on tumor formation in an orthotopic inoculation model. Oncol Rep 2019;42:1745-54. [PMID: 31485674 DOI: 10.3892/or.2019.7300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
227 Mori J, Tanikawa C, Ohnishi N, Funauchi Y, Toyoshima O, Ueda K, Matsuda K. EPSIN 3, A Novel p53 Target, Regulates the Apoptotic Pathway and Gastric Carcinogenesis. Neoplasia 2017;19:185-95. [PMID: 28152424 DOI: 10.1016/j.neo.2016.12.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
228 Gerson JN, Skariah S, Denlinger CS, Astsaturov I. Perspectives of HER2-targeting in gastric and esophageal cancer. Expert Opin Investig Drugs 2017;26:531-40. [PMID: 28387541 DOI: 10.1080/13543784.2017.1315406] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
229 Schaefer A, Der CJ. RHOA takes the RHOad less traveled to cancer. Trends Cancer 2022:S2405-8033(22)00092-9. [PMID: 35568648 DOI: 10.1016/j.trecan.2022.04.005] [Reference Citation Analysis]
230 Irino T, Takeuchi H, Terashima M, Wakai T, Kitagawa Y. Gastric Cancer in Asia: Unique Features and Management. Am Soc Clin Oncol Educ Book 2017;37:279-91. [PMID: 28561675 DOI: 10.1200/EDBK_175228] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
231 Song L, Guo Y, Xu B. Expressions of Ras Homolog Gene Family, Member A (RhoA) and Cyclooxygenase-2 (COX-2) Proteins in Early Gastric Cancer and Their Role in the Development of Gastric Cancer. Med Sci Monit 2017;23:2979-84. [PMID: 28624843 DOI: 10.12659/msm.902367] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
232 Yoon C, Cho SJ, Chang KK, Park DJ, Ryeom SW, Yoon SS. Role of Rac1 Pathway in Epithelial-to-Mesenchymal Transition and Cancer Stem-like Cell Phenotypes in Gastric Adenocarcinoma. Mol Cancer Res 2017;15:1106-16. [PMID: 28461325 DOI: 10.1158/1541-7786.MCR-17-0053] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
233 Nagamura Y, Miyazaki M, Nagano Y, Yuki M, Fukami K, Yanagihara K, Sasaki K, Sakai R, Yamaguchi H. PLEKHA5 regulates the survival and peritoneal dissemination of diffuse-type gastric carcinoma cells with Met gene amplification. Oncogenesis 2021;10:25. [PMID: 33677467 DOI: 10.1038/s41389-021-00314-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
234 Cho SY, Park JW, Liu Y, Park YS, Kim JH, Yang H, Um H, Ko WR, Lee BI, Kwon SY, Ryu SW, Kwon CH, Park DY, Lee JH, Lee SI, Song KS, Hur H, Han SU, Chang H, Kim SJ, Kim BS, Yook JH, Yoo MW, Kim BS, Lee IS, Kook MC, Thiessen N, He A, Stewart C, Dunford A, Kim J, Shih J, Saksena G, Cherniack AD, Schumacher S, Weiner AT, Rosenberg M, Getz G, Yang EG, Ryu MH, Bass AJ, Kim HK. Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers. Gastroenterology 2017;153:536-549.e26. [PMID: 28522256 DOI: 10.1053/j.gastro.2017.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
235 Yang H, Chen Z, Cao X, Li Z, Stavrakis S, Choo J, deMello AJ, Howes PD, He N. A sample-in-digital-answer-out system for rapid detection and quantitation of infectious pathogens in bodily fluids. Anal Bioanal Chem 2018;410:7019-30. [PMID: 30155705 DOI: 10.1007/s00216-018-1335-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
236 Ushiku T, Ishikawa S, Kakiuchi M, Tanaka A, Katoh H, Aburatani H, Lauwers GY, Fukayama M. RHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases. Gastric Cancer. 2015;Epub ahead of print. [PMID: 25823974 DOI: 10.1007/s10120-015-0493-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
237 Röcken C. Molecular classification of gastric cancer. Expert Rev Mol Diagn 2017;17:293-301. [PMID: 28118758 DOI: 10.1080/14737159.2017.1286985] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
238 Yang M, Arai E, Takahashi Y, Totsuka H, Chiku S, Taniguchi H, Katai H, Sakamoto H, Yoshida T, Kanai Y. Cooperative participation of epigenomic and genomic alterations in the clinicopathological diversity of gastric adenocarcinomas: significance of cell adhesion and epithelial-mesenchymal transition-related signaling pathways. Carcinogenesis 2020;41:1473-84. [PMID: 32710740 DOI: 10.1093/carcin/bgaa079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
239 Tanaka A, Ishikawa S, Ushiku T, Yamazawa S, Katoh H, Hayashi A, Kunita A, Fukayama M. Frequent CLDN18-ARHGAP fusion in highly metastatic diffuse-type gastric cancer with relatively early onset. Oncotarget 2018;9:29336-50. [PMID: 30034621 DOI: 10.18632/oncotarget.25464] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
240 Figueiredo C, Camargo MC, Leite M, Fuentes-Pananá EM, Rabkin CS, Machado JC. Pathogenesis of Gastric Cancer: Genetics and Molecular Classification. Curr Top Microbiol Immunol 2017;400:277-304. [PMID: 28124158 DOI: 10.1007/978-3-319-50520-6_12] [Cited by in Crossref: 19] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
241 Rokutan H, Abe H, Nakamura H, Ushiku T, Arakawa E, Hosoda F, Yachida S, Tsuji Y, Fujishiro M, Koike K, Totoki Y, Fukayama M, Shibata T. Initial and crucial genetic events in intestinal-type gastric intramucosal neoplasia. J Pathol. 2019;247:494-504. [PMID: 30474112 DOI: 10.1002/path.5208] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
242 Voena C, Chiarle R. RHO Family GTPases in the Biology of Lymphoma. Cells 2019;8:E646. [PMID: 31248017 DOI: 10.3390/cells8070646] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
243 Cai ZR, McCuaig C, Hatami A, Rivière JB, Marcoux D. A novel pathogenic RHOA variant in a patient with patterned cutaneous hypopigmentation associated with extracutaneous findings. Pediatr Dermatol 2022. [PMID: 35178721 DOI: 10.1111/pde.14923] [Reference Citation Analysis]
244 Zhang W. TCGA divides gastric cancer into four molecular subtypes: implications for individualized therapeutics. Chin J Cancer 2014;33:469-70. [PMID: 25223913 DOI: 10.5732/cjc.014.10117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 21] [Article Influence: 0.6] [Reference Citation Analysis]
245 Woo HY, Bae YS, Kim J, Lee SK, Lee YC, Cheong J, Noh SH, Kim H. Distinct expression profile of key molecules in crawling-type early gastric carcinoma. Gastric Cancer 2017;20:612-9. [DOI: 10.1007/s10120-016-0652-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
246 Ning FL, Zhang NN, Wang J, Jin YF, Quan HG, Pei JP, Zhao Y, Zeng XT, Abe M, Zhang CD. Prognostic value of modified Lauren classification in gastric cancer. World J Gastrointest Oncol 2021; 13(9): 1184-1195 [PMID: 34616522 DOI: 10.4251/wjgo.v13.i9.1184] [Reference Citation Analysis]
247 Abraham CG, Ludwig MP, Andrysik Z, Pandey A, Joshi M, Galbraith MD, Sullivan KD, Espinosa JM. ΔNp63α Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep 2018;24:3224-36. [PMID: 30232004 DOI: 10.1016/j.celrep.2018.08.058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
248 Ikari N, Aoyama S, Seshimo A, Suehiro Y, Motohashi T, Mitani S, Yoshina S, Tanji E, Serizawa A, Yamada T, Taniguchi K, Yamamoto M, Furukawa T. Somatic mutations and increased lymphangiogenesis observed in a rare case of intramucosal gastric carcinoma with lymph node metastasis. Oncotarget 2018;9:10808-17. [PMID: 29535844 DOI: 10.18632/oncotarget.24289] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
249 Choi S, Jang J, Heo YJ, Kang SY, Kim ST, Lee J, Kang WK, Kim JW, Kim KM. CDH1 mutations in gastric cancers are not associated with family history. Pathol Res Pract 2020;216:152941. [PMID: 32241597 DOI: 10.1016/j.prp.2020.152941] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
250 Sunakawa Y, Lenz HJ. Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network. Curr Treat Options Oncol. 2015;16:17. [PMID: 25813036 DOI: 10.1007/s11864-015-0331-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
251 Oue N, Sentani K, Sakamoto N, Yasui W. Clinicopathologic and molecular characteristics of gastric cancer showing gastric and intestinal mucin phenotype. Cancer Sci. 2015;106:951-958. [PMID: 26033320 DOI: 10.1111/cas.12706] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 5.6] [Reference Citation Analysis]
252 Ikari N, Taniguchi K, Serizawa A, Yamada T, Yamamoto M, Furukawa T. A primary tumor of mixed histological type is a novel poor prognostic factor for patients undergoing resection of liver metastasis from gastric cancer. J Hepatobiliary Pancreat Sci. 2017;24:281-288. [PMID: 28273395 DOI: 10.1002/jhbp.445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
253 Kim J, Kim M, Choi W, Moon M, Kim H, Lee J, Kim J, Kim S, Kang SG, Seo G, Kim P, Park J. Wnt3A Induces GSK-3β Phosphorylation and β-Catenin Accumulation Through RhoA/ROCK: RhoA INVOLVEMENT IN β-CATENIN ACTIVITY. J Cell Physiol 2017;232:1104-13. [DOI: 10.1002/jcp.25572] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
254 Huh YH, Oh S, Yeo YR, Chae IH, Kim SH, Lee JS, Yun SJ, Choi KY, Ryu JH, Jun CD, Song WK. Swiprosin-1 stimulates cancer invasion and metastasis by increasing the Rho family of GTPase signaling. Oncotarget 2015;6:13060-71. [PMID: 26079945 DOI: 10.18632/oncotarget.3637] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
255 Sato Y, Wada I, Odaira K, Hosoi A, Kobayashi Y, Nagaoka K, Karasaki T, Matsushita H, Yagi K, Yamashita H, Fujita M, Watanabe S, Kamatani T, Miya F, Mineno J, Nakagawa H, Tsunoda T, Takahashi S, Seto Y, Kakimi K. Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells. Clin Transl Immunology 2020;9:e1194. [PMID: 33101677 DOI: 10.1002/cti2.1194] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
256 Geng Q, Lao J, Zuo X, Chen S, Bei JX, Xu D. Identification of the distinct genomic features in gastroesophageal junction adenocarcinoma and its Siewert subtypes. J Pathol 2020;252:263-73. [PMID: 32715475 DOI: 10.1002/path.5516] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
257 Fukumura K, Kawazu M, Kojima S, Ueno T, Sai E, Soda M, Ueda H, Yasuda T, Yamaguchi H, Lee J, Shishido-hara Y, Sasaki A, Shirahata M, Mishima K, Ichimura K, Mukasa A, Narita Y, Saito N, Aburatani H, Nishikawa R, Nagane M, Mano H. Genomic characterization of primary central nervous system lymphoma. Acta Neuropathol 2016;131:865-75. [DOI: 10.1007/s00401-016-1536-2] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 13.3] [Reference Citation Analysis]
258 Hirotsu Y, Hada M, Amemiya K, Oyama T, Mochizuki H, Omata M. Multi-regional sequencing reveals clonal and polyclonal seeding from primary tumor to metastases in advanced gastric cancer. J Gastroenterol 2020;55:553-64. [PMID: 31912238 DOI: 10.1007/s00535-019-01659-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
259 Bijlsma MF, Sadanandam A, Tan P, Vermeulen L. Molecular subtypes in cancers of the gastrointestinal tract. Nat Rev Gastroenterol Hepatol 2017;14:333-42. [PMID: 28400627 DOI: 10.1038/nrgastro.2017.33] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 12.0] [Reference Citation Analysis]
260 Yeoh KG, Tan P. Mapping the genomic diaspora of gastric cancer. Nat Rev Cancer 2021. [PMID: 34702982 DOI: 10.1038/s41568-021-00412-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
261 Lee P, Weng S, Liu T, You H, Liao C, Wang M, Huang W. RHOA G17V mutation in angioimmunoblastic T-cell lymphoma: A potential biomarker for cytological assessment. Experimental and Molecular Pathology 2019;110:104294. [DOI: 10.1016/j.yexmp.2019.104294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
262 Molaei F, Forghanifard MM, Fahim Y, Abbaszadegan MR. Molecular Signaling in Tumorigenesis of Gastric Cancer. Iran Biomed J. 2018;22:217-230. [PMID: 29706061 DOI: 10.22034/ibj.22.4.217] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
263 Zhang J, Zhou Y, Tang PMK, Cheng ASL, Yu J, To KF, Kang W. Mechanotransduction and Cytoskeleton Remodeling Shaping YAP1 in Gastric Tumorigenesis. Int J Mol Sci 2019;20:E1576. [PMID: 30934860 DOI: 10.3390/ijms20071576] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
264 Tan P, Yeoh KG. Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma. Gastroenterology. 2015;149:1153-1162.e3. [PMID: 26073375 DOI: 10.1053/j.gastro.2015.05.059] [Cited by in Crossref: 190] [Cited by in F6Publishing: 180] [Article Influence: 27.1] [Reference Citation Analysis]
265 Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, Ye XS, Do IG, Liu S, Gong L, Fu J, Jin JG, Choi MG, Sohn TS, Lee JH, Bae JM, Kim ST, Park SH, Sohn I, Jung SH, Tan P, Chen R, Hardwick J, Kang WK, Ayers M, Hongyue D, Reinhard C, Loboda A, Kim S, Aggarwal A. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449-456. [PMID: 25894828 DOI: 10.1038/nm.3850] [Cited by in Crossref: 806] [Cited by in F6Publishing: 781] [Article Influence: 115.1] [Reference Citation Analysis]
266 Nagae G, Yamamoto S, Fujita M, Fujita T, Nonaka A, Umeda T, Fukuda S, Tatsuno K, Maejima K, Hayashi A, Kurihara S, Kojima M, Hishiki T, Watanabe K, Ida K, Yano M, Hiyama Y, Tanaka Y, Inoue T, Ueda H, Nakagawa H, Aburatani H, Hiyama E. Genetic and epigenetic basis of hepatoblastoma diversity. Nat Commun 2021;12:5423. [PMID: 34538872 DOI: 10.1038/s41467-021-25430-9] [Reference Citation Analysis]
267 Hoang T, Ganesan AK, Hiyama D, Dayyani F. Gene mutations distinguishing gastric from colorectal and esophageal adenocarcinomas. J Gastrointest Oncol 2020;11:45-54. [PMID: 32175104 DOI: 10.21037/jgo.2019.12.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
268 Wong SS, Kim KM, Ting JC, Yu K, Fu J, Liu S, Cristescu R, Nebozhyn M, Gong L, Yue YG. Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. Nat Commun. 2014;5:5477. [PMID: 25407104 DOI: 10.1038/ncomms6477] [Cited by in Crossref: 108] [Cited by in F6Publishing: 110] [Article Influence: 13.5] [Reference Citation Analysis]
269 Kuboki Y, Yamashita S, Niwa T, Ushijima T, Nagatsuma A, Kuwata T, Yoshino T, Doi T, Ochiai A, Ohtsu A. Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. Ann Oncol. 2016;27:127-133. [PMID: 26489445 DOI: 10.1093/annonc/mdv508] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
270 Fu Y, Feng MX, Yu J, Ma MZ, Liu XJ, Li J, Yang XM, Wang YH, Zhang YL, Ao JP, Xue F, Qin W, Gu J, Xia Q, Zhang ZG. DNA methylation-mediated silencing of matricellular protein dermatopontin promotes hepatocellular carcinoma metastasis by α3β1 integrin-Rho GTPase signaling. Oncotarget 2014;5:6701-15. [PMID: 25149533 DOI: 10.18632/oncotarget.2239] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
271 Iwashita Y, Ohnishi I, Matsushita Y, Ohtsuka S, Yamashita T, Inaba K, Fukazawa A, Ochiai H, Matsumoto K, Kurono N, Matsushima Y, Mori H, Suzuki S, Suzuki S, Tanioka F, Sugimura H. Geospatial Assessments of DNA Adducts in the Human Stomach: A Model of Field Cancerization. Cancers (Basel) 2021;13:3728. [PMID: 34359626 DOI: 10.3390/cancers13153728] [Reference Citation Analysis]
272 Dahmene M, Quirion L, Laurin M. High Throughput strategies Aimed at Closing the GAP in Our Knowledge of Rho GTPase Signaling. Cells 2020;9:E1430. [PMID: 32526908 DOI: 10.3390/cells9061430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
273 Ba M, Long H, Yan Z, Wang S, Wu Y, Tu Y, Gong Y, Cui S. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC. J Cell Biochem 2018;119:973-82. [PMID: 28681984 DOI: 10.1002/jcb.26264] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
274 Mclean MH, El-omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol 2014;11:664-74. [DOI: 10.1038/nrgastro.2014.143] [Cited by in Crossref: 222] [Cited by in F6Publishing: 216] [Article Influence: 27.8] [Reference Citation Analysis]
275 Nikaido M, Kakiuchi N, Miyamoto S, Hirano T, Takeuchi Y, Funakoshi T, Yokoyama A, Ogasawara T, Yamamoto Y, Yamada A, Setoyama T, Shimizu T, Kato Y, Uose S, Sakurai T, Minamiguchi S, Obama K, Sakai Y, Muto M, Chiba T, Ogawa S, Seno H. Indolent feature of Helicobacter pylori-uninfected intramucosal signet ring cell carcinomas with CDH1 mutations. Gastric Cancer 2021;24:1102-14. [PMID: 33961152 DOI: 10.1007/s10120-021-01191-8] [Reference Citation Analysis]
276 Jung H, Yoon SR, Lim J, Cho HJ, Lee HG. Dysregulation of Rho GTPases in Human Cancers. Cancers (Basel) 2020;12:E1179. [PMID: 32392742 DOI: 10.3390/cancers12051179] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
277 Nakamura Y, Sasaki A, Yukami H, Jogo T, Kawazoe A, Kuboki Y, Taniguchi H, Yamashita R, Kuwata T, Ozawa M, Nakamura M, Yoshino T, Shitara K. Emergence of Concurrent Multiple EGFR Mutations and MET Amplification in a Patient With EGFR-Amplified Advanced Gastric Cancer Treated With Cetuximab. JCO Precis Oncol 2020;4:PO. [PMID: 33283138 DOI: 10.1200/PO.20.00263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
278 Chen Y, Zhou Q, Wang H, Zhuo W, Ding Y, Lu J, Wu G, Xu N, Teng L. Predicting Peritoneal Dissemination of Gastric Cancer in the Era of Precision Medicine: Molecular Characterization and Biomarkers. Cancers (Basel) 2020;12:E2236. [PMID: 32785164 DOI: 10.3390/cancers12082236] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
279 Xu J, Li N, Deng W, Luo S. Discovering the mechanism and involvement of the methylation of cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and its special locus region in gastric cancer. Bioengineered 2021;12:1286-98. [PMID: 33896386 DOI: 10.1080/21655979.2021.1887646] [Reference Citation Analysis]
280 Buti L, Ruiz-Puig C, Sangberg D, Leissing TM, Brewer RC, Owen RP, Sgromo B, Royer C, Ebner D, Lu X. CagA-ASPP2 complex mediates loss of cell polarity and favors H. pylori colonization of human gastric organoids. Proc Natl Acad Sci U S A 2020;117:2645-55. [PMID: 31964836 DOI: 10.1073/pnas.1908787117] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
281 Lin X, Zhao Y, Song WM, Zhang B. Molecular classification and prediction in gastric cancer. Comput Struct Biotechnol J 2015;13:448-58. [PMID: 26380657 DOI: 10.1016/j.csbj.2015.08.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
282 Huang W, Zhao S, Zhang C, Li Z, Ge S, Lian B, Feng H, Wang K, Xu R, Ji J, Gao J, Shi W, Shen L. Identification of "regulation of RhoA activity panel" as a prognostic and predictive biomarker for gastric cancer. Aging (Albany NY) 2020;13:714-34. [PMID: 33288739 DOI: 10.18632/aging.202179] [Reference Citation Analysis]
283 Sugimoto S, Komatsu H, Morohoshi Y, Kanai T. Recognition of and recent issues in hereditary diffuse gastric cancer. J Gastroenterol. 2015;50:831-843. [PMID: 26049741 DOI: 10.1007/s00535-015-1093-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
284 Figueiredo C, Costa S, Karameris A, Machado JC. Pathogenesis of Gastric Cancer. Helicobacter 2015;20 Suppl 1:30-5. [PMID: 26372822 DOI: 10.1111/hel.12254] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
285 Funakoshi T, Miyamoto S, Kakiuchi N, Nikaido M, Setoyama T, Yokoyama A, Horimatsu T, Yamada A, Torishima M, Kosugi S, Yamada H, Sugimura H, Haga H, Sakai Y, Ogawa S, Seno H, Muto M, Chiba T. Genetic analysis of a case of Helicobacter pylori-uninfected intramucosal gastric cancer in a family with hereditary diffuse gastric cancer. Gastric Cancer. 2019;22:892-898. [PMID: 30542785 DOI: 10.1007/s10120-018-00912-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
286 Timmins MA, Wagner SD, Ahearne MJ. The new biology of PTCL-NOS and AITL: current status and future clinical impact. Br J Haematol 2020;189:54-66. [PMID: 32064593 DOI: 10.1111/bjh.16428] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
287 Zhu F, Li F, Deng L, Meng F, Liang Z. Protein Interaction Network Reconstruction with a Structural Gated Attention Deep Model by Incorporating Network Structure Information. J Chem Inf Model 2022. [PMID: 35005980 DOI: 10.1021/acs.jcim.1c00982] [Reference Citation Analysis]
288 Song Y, Wang Y, Tong C, Xi H, Zhao X, Wang Y, Chen L. A unified model of the hierarchical and stochastic theories of gastric cancer. Br J Cancer 2017;116:973-89. [PMID: 28301871 DOI: 10.1038/bjc.2017.54] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
289 Lee J, Bass AJ, Ajani JA. Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. American Society of Clinical Oncology Educational Book 2016. [DOI: 10.1200/edbk_159091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
290 Chiba S, Sakata-Yanagimoto M. Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia 2020;34:2592-606. [PMID: 32704161 DOI: 10.1038/s41375-020-0990-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
291 Kang W, Cheng AS, Yu J, To KF. Emerging role of Hippo pathway in gastric and other gastrointestinal cancers. World J Gastroenterol 2016; 22(3): 1279-1288 [PMID: 26811664 DOI: 10.3748/wjg.v22.i3.1279] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
292 Jia F, Teer JK, Knepper TC, Lee JK, Zhou HH, He YJ, McLeod HL. Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer. Mol Diagn Ther 2017;21:179-85. [PMID: 28039579 DOI: 10.1007/s40291-016-0250-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
293 Ghadie M, Xia Y. Mutation Edgotype Drives Fitness Effect in Human. Front Bioinform 2021;1:690769. [DOI: 10.3389/fbinf.2021.690769] [Reference Citation Analysis]
294 Li S, Zhao W, Sun M. An Analysis Regarding the Association Between the ISLR Gene and Gastric Carcinogenesis. Front Genet 2020;11:620. [PMID: 32612640 DOI: 10.3389/fgene.2020.00620] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
295 Li Y, Dai Z, Huang G, Jin Y, Ning Z, Shen J. Low-abundance mutations in colorectal cancer patients and healthy adults. Aging (Albany NY) 2020;12:808-24. [PMID: 31927530 DOI: 10.18632/aging.102657] [Reference Citation Analysis]
296 Nagata Y, Kontani K, Enami T, Kataoka K, Ishii R, Totoki Y, Kataoka TR, Hirata M, Aoki K, Nakano K, Kitanaka A, Sakata-Yanagimoto M, Egami S, Shiraishi Y, Chiba K, Tanaka H, Shiozawa Y, Yoshizato T, Suzuki H, Kon A, Yoshida K, Sato Y, Sato-Otsubo A, Sanada M, Munakata W, Nakamura H, Hama N, Miyano S, Nureki O, Shibata T, Haga H, Shimoda K, Katada T, Chiba S, Watanabe T, Ogawa S. Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood 2016;127:596-604. [PMID: 26574607 DOI: 10.1182/blood-2015-06-644948] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 9.7] [Reference Citation Analysis]
297 Lin Y, Wu Z, Guo W, Li J. Gene mutations in gastric cancer: a review of recent next-generation sequencing studies. Tumour Biol. 2015;36:7385-7394. [PMID: 26364057 DOI: 10.1007/s13277-015-4002-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
298 Hayakawa Y, Ariyama H, Stancikova J, Sakitani K, Asfaha S, Renz BW, Dubeykovskaya ZA, Shibata W, Wang H, Westphalen CB, Chen X, Takemoto Y, Kim W, Khurana SS, Tailor Y, Nagar K, Tomita H, Hara A, Sepulveda AR, Setlik W, Gershon MD, Saha S, Ding L, Shen Z, Fox JG, Friedman RA, Konieczny SF, Worthley DL, Korinek V, Wang TC. Mist1 Expressing Gastric Stem Cells Maintain the Normal and Neoplastic Gastric Epithelium and Are Supported by a Perivascular Stem Cell Niche. Cancer Cell. 2015;28:800-814. [PMID: 26585400 DOI: 10.1016/j.ccell.2015.10.003] [Cited by in Crossref: 160] [Cited by in F6Publishing: 155] [Article Influence: 22.9] [Reference Citation Analysis]
299 Nishimura S, Yashiro M, Sera T, Yamamoto Y, Kushitani Y, Sugimoto A, Kushiyama S, Togano S, Kuroda K, Okuno T, Murakami Y, Ohira M. Serine threonine kinase 11/liver kinase B1 mutation in sporadic scirrhous-type gastric cancer cells. Carcinogenesis 2020;41:1616-23. [PMID: 32236518 DOI: 10.1093/carcin/bgaa031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
300 Matsuoka T, Yashiro M. Precision medicine for gastrointestinal cancer: Recent progress and future perspective. World J Gastrointest Oncol 2020; 12(1): 1-20 [PMID: 31966910 DOI: 10.4251/wjgo.v12.i1.1] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
301 Zandvakili I, Lin Y, Morris JC, Zheng Y. Rho GTPases: Anti- or pro-neoplastic targets? Oncogene 2017;36:3213-22. [PMID: 27991930 DOI: 10.1038/onc.2016.473] [Cited by in F6Publishing: 52] [Reference Citation Analysis]
302 Nie Y, Wu K, Yu J, Liang Q, Cai X, Shang Y, Zhou J, Pan K, Sun L, Fang J, Yuan Y, You W, Fan D. A global burden of gastric cancer: the major impact of China. Expert Rev Gastroenterol Hepatol. 2017;11:651-661. [PMID: 28351219 DOI: 10.1080/17474124.2017.1312342] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
303 Kim SY, Park C, Kim HJ, Park J, Hwang J, Kim JI, Choi MG, Kim S, Kim KM, Kang MS. Deregulation of immune response genes in patients with Epstein-Barr virus-associated gastric cancer and outcomes. Gastroenterology. 2015;148:137-147.e9. [PMID: 25254613 DOI: 10.1053/j.gastro.2014.09.020] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 8.3] [Reference Citation Analysis]
304 Chang HR, Nam S, Lee J, Kim JH, Jung HR, Park HS, Park S, Ahn YZ, Huh I, Balch C, Ku JL, Powis G, Park T, Jeong JH, Kim YH. Systematic approach identifies RHOA as a potential biomarker therapeutic target for Asian gastric cancer. Oncotarget. 2016;7:81435-81451. [PMID: 27806312 DOI: 10.18632/oncotarget.12963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
305 Porter AP, Papaioannou A, Malliri A. Deregulation of Rho GTPases in cancer. Small GTPases 2016;7:123-38. [PMID: 27104658 DOI: 10.1080/21541248.2016.1173767] [Cited by in Crossref: 102] [Cited by in F6Publishing: 99] [Article Influence: 17.0] [Reference Citation Analysis]
306 Kasuya K, Nagakawa Y, Hosokawa Y, Sahara Y, Takishita C, Nakajima T, Hijikata Y, Soya R, Katsumata K, Tsuchida A. RhoA activity increases due to hypermethylation of ARHGAP28 in a highly liver-metastatic colon cancer cell line. Biomed Rep 2016;4:335-9. [PMID: 26998271 DOI: 10.3892/br.2016.582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
307 Konen J, Wilkinson S, Lee B, Fu H, Zhou W, Jiang Y, Marcus AI. LKB1 kinase-dependent and -independent defects disrupt polarity and adhesion signaling to drive collagen remodeling during invasion. Mol Biol Cell. 2016;27:1069-1084. [PMID: 26864623 DOI: 10.1091/mbc.E15-08-0569] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
308 Ichikawa H, Nagahashi M, Shimada Y, Hanyu T, Ishikawa T, Kameyama H, Kobayashi T, Sakata J, Yabusaki H, Nakagawa S, Sato N, Hirata Y, Kitagawa Y, Tanahashi T, Yoshida K, Nakanishi R, Oki E, Vuzman D, Lyle S, Takabe K, Ling Y, Okuda S, Akazawa K, Wakai T. Actionable gene-based classification toward precision medicine in gastric cancer. Genome Med. 2017;9:93. [PMID: 29089060 DOI: 10.1186/s13073-017-0484-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
309 Lin Y, Zheng Y. Approaches of targeting Rho GTPases in cancer drug discovery. Expert Opin Drug Discov 2015;10:991-1010. [PMID: 26087073 DOI: 10.1517/17460441.2015.1058775] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 9.7] [Reference Citation Analysis]
310 Zhang YL, Xing X, Cai LB, Zhu L, Yang XM, Wang YH, Yang Q, Nie HZ, Zhang ZG, Li J, Zhang XL. Integrin α9 Suppresses Hepatocellular Carcinoma Metastasis by Rho GTPase Signaling. J Immunol Res 2018;2018:4602570. [PMID: 29951557 DOI: 10.1155/2018/4602570] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
311 Yamashita K, Hosoda K, Niihara M, Hiki N. History and emerging trends in chemotherapy for gastric cancer. Ann Gastroenterol Surg 2021;5:446-56. [PMID: 34337293 DOI: 10.1002/ags3.12439] [Reference Citation Analysis]
312 Ahn S, Lee SJ, Kim Y, Kim A, Shin N, Choi KU, Lee CH, Huh GY, Kim KM, Setia N, Lauwers GY, Park DY. High-throughput Protein and mRNA Expression-based Classification of Gastric Cancers Can Identify Clinically Distinct Subtypes, Concordant With Recent Molecular Classifications. Am J Surg Pathol. 2017;41:106-115. [PMID: 27819872 DOI: 10.1097/pas.0000000000000756] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 9.2] [Reference Citation Analysis]
313 Yu SR, Huang XJ, Zhang YP. Gastric cancer related genes. Shijie Huaren Xiaohua Zazhi 2016; 24(32): 4381-4388 [DOI: 10.11569/wcjd.v24.i32.4381] [Reference Citation Analysis]
314 Hodge RG, Schaefer A, Howard SV, Der CJ. RAS and RHO family GTPase mutations in cancer: twin sons of different mothers? Crit Rev Biochem Mol Biol 2020;55:386-407. [PMID: 32838579 DOI: 10.1080/10409238.2020.1810622] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
315 Takaoka S, Hirotsu Y, Ohyama H, Mochizuki H, Amemiya K, Oyama T, Ashizawa H, Yoshimura D, Nakagomi K, Hosoda K, Suzuki Y, Kojima Y, Omata M. Molecular subtype switching in early-stage gastric cancers with multiple occurrences. J Gastroenterol 2019;54:674-86. [DOI: 10.1007/s00535-019-01547-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
316 Cordova-Delgado M, Pinto MP, Retamal IN, Muñoz-Medel M, Bravo ML, Fernández MF, Cisternas B, Mondaca S, Sanchez C, Galindo H, Nervi B, Ibáñez C, Acevedo F, Madrid J, Peña J, Koch E, Maturana MJ, Romero D, de la Jara N, Torres J, Espinoza M, Balmaceda C, Liao Y, Li Z, Freire M, Gárate-Calderón V, Cáceres J, Sepúlveda-Hermosilla G, Lizana R, Ramos L, Artigas R, Norero E, Crovari F, Armisén R, Corvalán AH, Owen GI, Garrido M. High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study. Cancers (Basel) 2019;11:E1275. [PMID: 31480291 DOI: 10.3390/cancers11091275] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
317 Hinsenkamp I, Schulz S, Roscher M, Suhr AM, Meyer B, Munteanu B, Fuchser J, Schoenberg SO, Ebert MP, Wängler B, Hopf C, Burgermeister E. Inhibition of Rho-Associated Kinase 1/2 Attenuates Tumor Growth in Murine Gastric Cancer. Neoplasia 2016;18:500-11. [PMID: 27566106 DOI: 10.1016/j.neo.2016.07.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]